Glucagon derivative and a composition comprising a long acting conjugate of the same

ABSTRACT

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 16/812,011(allowed) filed Mar. 6, 2020, which is a continuation of applicationSer. No. 15/740,668 filed Dec. 28, 2017, now U.S. Pat. No. 10,696,725issued Jun. 30, 2020, which is a National Stage of InternationalApplication No. PCT/KR2016/006984 filed Jun. 29, 2016, claiming prioritybased on Korean Patent Application No. 10-2015-0093265, filed Jun. 30,2015, the contents of all of which are incorporated herein by referencein their entireties.

SEQUENCE LISTING

The content of the electronically submitted sequence listing, file name:Sequence_Listing_As_Filed.txt; size: 28,709 bytes; and date of creation:Jan. 14, 2022, filed herewith, is incorporated herein by reference inits entirety.

TECHNICAL FIELD

The present invention relates to a glucagon derivative, a long-actingconjugate of the glucagon derivative, and a use thereof.

BACKGROUND ART

Due to recent economic growth and changes in dietary habits, etc., theincidence of metabolic syndrome-associated diseases including variousdiseases such as obesity, hyperlipidemia, hypertension,arteriosclerosis, hyperinsulinemia, diabetes, and liver diseases israpidly increasing. These diseases may occur independently but ingeneral they mostly occur in close relationship with each other, beingaccompanied by various symptoms.

In particular, according to the World Health Organization (WHO), morethan one billion adults are overweight worldwide, among them over 3million are clinically obese, and 250,000 people die every year inEurope and more than 2.5 million people worldwide die every year due tooverweight-related diseases.

Overweight and obesity are responsible for increasing blood pressure andcholesterol levels and causing or worsening various diseases, such ascardiac diseases, diabetes, arthritis, etc. In addition, the problem ofobesity is also becoming a major cause in the increased incidence ofarteriosclerosis, hypertension, hyperlipidemia, or heart diseases inchildren or teenagers as well as in adults.

Although obesity is a severe condition that causes various diseasesworldwide as described above, it is thought to be overcome by individualeffort, and it is also believed that obese patients lack self-control.However, obesity is not easy to treat, because it is a complex diseaseassociated with the mechanisms of appetite control and energymetabolism.

Accordingly, the treatment of obesity requires not only the efforts ofobese patients, but also a method capable of treating abnormalmechanisms associated with appetite control and energy metabolism. Thus,efforts have been made to develop drugs for treating the abnormalmechanisms.

As a result of these efforts, drugs such as RIMONABANT®(Sanofi-Aventis), SIBUTRAMIN® (Abbott), CONTRAVE® (Takeda), ORLISTAT®(Roche), etc have been developed, but they have the disadvantages ofserious adverse effects or very weak anti-obesity effects. For example,according to a report, RIMONABANT® shows a side-effect of centralnervous system disorder, SIBUTRAMINE® and CONTRAVE® show cardiovascularside-effects, and ORLISTAT® shows only about 4 kg of weight loss whentaken for one year. Accordingly, there are no therapeutic agents forobesity which can be prescribed safely for obese patients.

Many extensive studies have been made to develop novel therapeuticagents for obesity which can resolve the problems of the conventionalanti-obesity drugs. Recently, glucagon derivatives have received muchattention. Glucagon is produced by the pancreas when blood glucoselevels drop as a result of other medications or diseases, or hormone orenzyme deficiencies. Glucagon sends a signal for glycogen breakdown inthe liver and a subsequent glucose release and plays a role inincreasing blood glucose levels to a normal range. In addition to theeffect of increasing the blood glucose levels, glucagon suppressesappetite and activates hormone-sensitive lipase of adipocytes tofacilitate lipolysis, thereby showing an anti-obesity effect. However,the use of glucagon as a therapeutic agent has been limited because ithas a low solubility and it is precipitated at a neutral pH.

Accordingly, the glucagon with improved properties alone can beeffectively used for the treatment of severe hypoglycemia, nonalcoholicsteatohepatitis (NASH), dyslipidemia, etc., due to its activities of fatdecomposition and β-oxydation in the liver.

One of the glucagon derivatives, glucagon-like peptide-1 (GLP-1), isunder development as a therapeutic agent for treating hyperglycemia inpatients with diabetes. GLP-1 has the functions of stimulating insulinsynthesis and secretion, inhibiting glucagon secretion, slowing gastricemptying, increasing glucose utilization, and inhibiting food intake.

Exendin-4, prepared from lizard venom and having an amino acid homologyof about 50% with GLP-1, was also reported to activate the GLP-1receptor, thereby improving hyperglycemia in patients with diabetes (JBiol Chem. 1992 Apr. 15; 267 (11): 7402-5). However, anti-obesity drugscontaining GLP-1 are reported to show side-effects such as vomiting andnausea.

As an alternative to GLP-1, therefore, much attention has been focusedon oxyntomodulin, which can bind to both receptors of the two peptides,GLP-1 and glucagon. Oxyntomodulin is a peptide prepared from a glucagonprecursor, pre-glucagon, and has the functions of inhibiting food intakeand enhancing satiety of GLP-1, and has lipolytic activity likeglucagon, thus increasing its potency in anti-obesity therapy.

However, oxyntomodulin or derivatives thereof have a serious drawback inthat an excess amount of the drug should be administered daily becausethey have low efficacy and a short in vivo half-life.

Additionally, when both activities of GLP-1 and glucagon are present ina single peptide, the activity ratio thereof becomes fixed, and thus itis difficult to use a dual agonist with various ratios. Accordingly, acombined therapy capable of using various activity ratios by adjustingthe contents of GLP-1 and glucagon may be more effective. However, forthe combined therapy, it is required to improve the physicalcharacteristics of glucagon, which aggregates at a neutral pH andprecipitates with time, thus showing poor solubility.

Under these circumstances, the present inventors have developed glucagonderivatives with partial modifications of the amino acid sequence ofglucagon for improving the therapeutic effects of glucagon onhypoglycemia and obesity by improving the physical properties ofglucagon, and have discovered that these glucagon derivatives, due tothe altered pI values which are different from that of native glucagon,have improved solubility and higher stability at a neutral pH and haveconfirmed that the developed glucagon derivative activates its receptorsin in vitro assay, thereby completing the present invention.

DISCLOSURE Technical Problem

An object of the present invention is to provide a pharmaceuticalcomposition for treating or preventing metabolic syndrome, containing aglucagon derivative and at least one compound or material having atherapeutic activity for metabolic syndrome.

Another object of the present invention is to provide a novel glucagonderivative.

Still another object of the present invention is to provide an isolatedpolynucleotide encoding the glucagon derivative, a vector including thepolynucleotide, and an isolated cell including the polynucleotide or thevector.

Still another object of the present invention is to provide an isolatedconjugate in which a glucagon derivative and a biocompatible materialwhich is capable of increasing in vivo half-life are linked.

Still another object of the present invention is to provide acomposition containing the glucagon derivative and the isolatedconjugate.

Still another object of the present invention is to provide apharmaceutical composition for treating or preventing hypoglycemia ormetabolic syndrome, containing the glucagon derivative or the isolatedconjugate.

Still another object of the present invention is to provide a method forpreventing or treating hypoglycemia or metabolic syndrome includingadministering the above composition to the subject in need thereof.

Still another object of the present invention is to provide use of theglucagon derivative or the isolated conjugate or the composition in thepreparation of a medicament (or a pharmaceutical composition) forpreventing or treating hypoglycemia or metabolic syndrome.

Technical Solution

In order to achieve the above objects, an aspect of the presentinvention provides a pharmaceutical composition for treating orpreventing metabolic syndrome containing a glucagon derivative and atleast one compound or material which has a therapeutic activity formetabolic syndrome.

More specifically, an aspect of the present invention provides apharmaceutical composition for treating or preventing metabolicsyndrome, which contains: i) a peptide including the amino acid sequenceof the following General Formula 1, and ii) at least one compound ormaterial having a therapeutic activity for metabolic syndrome:

X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-W-L-X27-X28-X29-X30  (GeneralFormula 1, SEQ ID NO: 45)

In General Formula 1,

X1 is histidine, desamino-histidyl, N-dimethyl-histidyl, β-hydroxyimidazopropionyl, 4-imidazoacetyl, β-carboxy imidazopropionyl,tryptophan, or tyrosine, or is absent;

X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine,glycine, Sar(N-methylglycine), serine, or D-serine;

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid, glutamic acid, or cysteine;

X16 is glutamic acid, aspartic acid, serine, α-methyl-glutamic acid, orcysteine, or is absent;

X17 is aspartic acid, glutamine, glutamic acid, lysine, arginine,serine, cysteine, or valine, or is absent;

X18 is alanine, aspartic acid, glutamic acid, arginine, valine, orcysteine, or is absent;

X19 is alanine, arginine, serine, valine, or cysteine, or is absent;

X20 is lysine, histidine, glutamine, aspartic acid, lysine, arginine,α-methyl-glutamic acid, or cysteine, or is absent;

X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine, or isabsent;

X23 is isoleucine, valine, or arginine, or is absent;

X24 is valine, arginine, alanine, cysteine, glutamic acid, lysine,glutamine, α-methyl-glutamic acid, or leucine, or is absent;

X27 is isoleucine, valine, alanine, lysine, methionine, glutamine, orarginine, or is absent;

X28 is glutamine, lysine, asparagine, or arginine, or is absent;

X29 is lysine, alanine, glycine, or threonine, or is absent; and

X30 is cysteine, or is absent;

with the proviso that when the amino acid sequence of General Formula 1is identical to SEQ ID NO: 1, it is excluded.

In another specific embodiment,

in General Formula 1,

X1 is histidine, tryptophan, or tyrosine, or is absent;

X2 is serine or aminoisobutyric acid (Aib);

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine, or cysteine;

X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine,or valine;

X18 is aspartic acid, glutamic acid, arginine, or cysteine;

X19 is alanine or cysteine;

X20 is glutamine, aspartic acid, lysine, or cysteine;

X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine;

X23 is isoleucine, valine, or arginine;

X24 is valine, arginine, alanine, glutamic acid, lysine, glutamine, orleucine;

X27 is isoleucine, valine, alanine, methionine, glutamine, or arginine;

X28 is glutamine, lysine, asparagine, or arginine;

X29 is threonine; and

X30 is cysteine or is absent.

In still another specific embodiment, in General Formula 1,

X1 is histidine, tryptophan, or tyrosine, or is absent;

X2 is serine or aminoisobutyric acid (Aib);

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine, or cysteine;

X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine,or valine;

X18 is aspartic acid, glutamic acid, arginine, or cysteine;

X19 is alanine or cysteine;

X20 is glutamine, aspartic acid, or lysine;

X21 is aspartic acid or glutamic acid;

X23 is valine;

X24 is valine or glutamine;

X27 is isoleucine or methionine;

X28 is asparagine or arginine;

X29 is threonine; and

X30 is cysteine or is absent.

In still another specific embodiment, in General Formula 1,

X1 is tyrosine, X2 is aminoisobutyric acid (Aib);

X7 is threonine;

X10 is tyrosine;

X12 is lysine;

X13 is tyrosine;

X14 is leucine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine, or cysteine;

X17 is lysine or arginine;

X18 is arginine;

X19 is alanine;

X20 is glutamine, cysteine, or lysine;

X21 is aspartic acid, cysteine, valine, or glutamic acid;

X23 is valine;

X24 is valine or arginine;

X27 is methionine;

X28 is asparagine or arginine;

X29 is threonine; and

X30 is absent.

In still another specific embodiment, the above peptide is characterizedin that it is a peptide including the amino acid sequence of thefollowing General Formula 2:

Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-M-N-T-X30  (GeneralFormula 2, SEQ ID NO: 46)

In General Formula 2,

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid or serine;

X17 is lysine or arginine;

X20 is glutamine or lysine;

X21 is aspartic acid or glutamic acid;

X24 is valine or glutamine; and

X30 is cysteine or is absent,

wherein, among the peptides including the amino acid sequence of GeneralFormula 2, the peptides corresponding to SEQ ID NOS: 14, 19, 20, 25, 27,31, and 33 may be excluded.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that it has a pIvalue different to that of native glucagon, e.g., a pI of 6.5 or less,or a pI of 7.0 or higher.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that at least oneamino acid pair among the amino acid pairs of X10 and X14, X12 and X16,X16 and X20, X17 and X21, X20 and X24, and X24 and X28 in GeneralFormula 1 is substituted with glutamic acid or lysine, which is capableof forming a ring, respectively.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that the aminoacid pair of X12 and X16 or the amino acid pair of X16 and X20 isrespectively substituted with glutamic acid or lysine, which is capableof forming a ring.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that at least oneamino acid pair among the amino acid pairs of X10 and X14, X12 and X16,X16 and X20, X17 and X21, X20 and X24, and X24 and X28 in GeneralFormula 1 forms a ring (e.g., a lactam ring).

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that theC-terminus of the peptide is amidated.

In still another specific embodiment, the peptide including the aminoacid sequence of the following General Formula 1 is characterized inthat it is a glucagon derivative capable of activating a glucagonreceptor.

In still another specific embodiment, the peptide is characterized inthat it includes an amino acid sequence selected from the groupconsisting of SEQ ID NOS: 2 to 44.

In still another specific embodiment, the peptide is characterized inthat it includes an amino acid sequence selected from the groupconsisting of SEQ ID NOS: 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to44.

In still another specific embodiment, the peptide is characterized inthat it includes an amino acid sequence of SEQ ID NO: 12 or SEQ ID NO:20.

In still another specific embodiment, the compound or material having atherapeutic activity for metabolic syndrome is characterized in that itis selected from the group consisting of an insulinotropic peptide, aglucagon-like peptide-1 (GLP-1) receptor agonist, a leptin receptoragonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, a Y5 receptorantagonist, a melanin-concentrating hormone (MCH) receptor antagonist, aY2/4 receptor agonist, a melanocortin 3/4 (MC 3/4) receptor agonist, agastric/pancreatic lipase inhibitor, an agonist of 5-hydroxytryptaminereceptor 2C (5HT2C), a β3A receptor agonist, an amylin receptor agonist,a ghrelin antagonist, a ghrelin receptor antagonist, a peroxisomeproliferator-activated receptor alpha (PPARα) agonist, a peroxisomeproliferator-activated receptor delta (PPARδ) agonist, a Farnesoid Xreceptor (FXR) agonist, an acetyl-CoA carboxylase inhibitor, a peptideYY, cholecystokinin (CCK), xenin, glicentin, obestatin, secretin,nesfatin, insulin, and a glucose-dependent insulinotropic peptide (GIP).

In still another specific embodiment, the insulinotropic peptide ischaracterized in that it is selected from the group consisting of GLP-1,exendin-3, exendin-4, an agonist thereof, a derivative thereof, afragment thereof, a variant thereof, and a combination thereof.

In still another specific embodiment, the insulinotropic peptide ischaracterized in that it is an insulinotropic peptide derivative inwhich the N-terminal histidine residue of the insulinotropic peptide issubstituted with one selected from the group consisting ofdesamino-histidyl, N-dimethyl-histidyl, β-hydroxy imidazopropionyl,4-imidazoacetyl, and β-carboxy imidazopropionyl.

In still another specific embodiment, the insulinotropic peptide ischaracterized in that it is selected from the group consisting of anative exendin-4; an exendin-4 derivative in which the N-terminal aminegroup of exendin-4 is deleted; an exendin-4 derivative in which theN-terminal amine group of exendin-4 is substituted with a hydroxylgroup; an exendin-4 derivative in which the N-terminal amine group ofexendin-4 is modified with a dimethyl group; an exendin-4 derivative inwhich the α-carbon of the 1^(st) amino acid of exendin-4, histidine, isdeleted; an exendin-4 derivative in which the 12^(th) amino acid ofexendin-4, lysine, is substituted with serine, and an exendin-4derivative in which the 12^(th) amino acid of exendin-4, lysine, issubstituted with arginine.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 is characterized in that the peptideincluding the amino acid sequence of General Formula 1 is in the form ofa long-acting conjugate to which a biocompatible material capable ofincreasing in vivo half-life of the peptide is linked; and theinsulinotropic peptide is in the form of a long-acting conjugate towhich a biocompatible material capable of increasing in vivo half-lifeof the insulinotropic peptide is linked.

In still another specific embodiment, the biocompatible material ischaracterized in that it is selected from the group consisting ofpolyethylene glycol, fatty acid, cholesterol, albumin and a fragmentthereof, an albumin-binding material, a polymer of repeating units of aparticular amino acid sequence, an antibody, an antibody fragment, anFcRn-binding material, in vivo connective tissue or a derivativethereof, a nucleotide, fibronectin, transferrin, a saccharide, and apolymer.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 1 and the insulinotropic peptide arecharacterized in that they are respectively linked to a biocompatiblematerial by a linker selected from the group consisting of polyethyleneglycol, polypropylene glycol, an ethylene glycol-propylene glycolcopolymer, polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide,dextran, polyvinyl ethyl ether, a biodegradable polymer such aspolylactic acid (PLA) and polylactic-glycolic acid (PLGA), lipidpolymer, chitin, hyaluronic acid, fatty acid, a polymer, a low molecularweight compound, a nucleotide, and a combination thereof.

In still another specific embodiment, the biocompatible material ischaracterized in that it is an FcRn-binding material, and the peptideincluding the amino acid sequence of General Formula 1 and theinsulinotropic peptide are respectively linked to a biocompatiblematerial by a peptide linker or a non-peptide linker selected from thegroup consisting of polyethylene glycol, polypropylene glycol, anethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,polyvinyl alcohol, a polysaccharide, polyvinyl ethyl ether, dextran, abiodegradable polymer such as polylactic acid (PLA) andpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,and a combination thereof.

In still another specific embodiment, the FcRn-binding material ischaracterized in that it is a polypeptide including an immunoglobulin Fcregion.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is aglycosylated.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is selected from the group consisting of:

(a) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain;

(b) a CH1 domain and a CH2 domain;

(c) a CH1 domain and a CH3 domain;

(d) a CH2 domain and a CH3 domain;

(e) a combination between one or two or more domains among a CH1 domain,a CH2 domain, a CH3 domain, and a CH4 domain and an immunoglobulin hingeregion or a part of the hinge region; and

(f) a dimer between each domain of the heavy chain constant region andthe light chain constant region.

In still another specific embodiment, the polypeptide including theimmunoglobulin Fc region is in the form of a dimer.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is a native Fc derivative in which the regioncapable of forming a disulfide bond is deleted, a native Fc derivativein which a part of the amino acid(s) in the N-terminus is deleted, anative Fc derivative in which a methionine is added to the N-terminus, anative Fc derivative in which a complement-binding site is deleted, or anative Fc derivative in which an antibody dependent cell mediatedcytotoxicity (ADCC) site is deleted.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is an Fc region derived from an immunoglobulinselected from the group consisting of IgG, IgA, IgD, IgE, and IgM.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is an IgG4 Fc region.

In still another specific embodiment, the immunoglobulin Fc region ischaracterized in that it is an aglycosylated Fc region derived fromhuman IgG4.

In still another specific embodiment, the non-peptide linker ischaracterized in that it is linked to the cysteine residue of a peptideincluding the amino acid sequence of General Formula 1.

In still another specific embodiment, the non-peptide linker ischaracterized in that both ends of the non-peptide linker arerespectively linked to an amine group or a thiol group of a peptide,which includes the amino acid sequence of General Formula 1, or aninsulinotropic peptide, and a biocompatible material.

In still another specific embodiment, the metabolic syndrome ischaracterized in that it is selected from the group consisting ofimpaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity,diabetes, hypertension, nonalcoholic steatohepatitis (NASH),atherosclerosis caused by dyslipidemia, atherosclerosis,arteriosclerosis, coronary heart disease, and stroke.

In another aspect, the present invention provides a novel glucagonderivative.

In a specific embodiment, the glucagon derivative is characterized inthat it is an isolated peptide including the amino acid sequence of thefollowing General Formula 2:

Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-M-N-T-X30  (GeneralFormula 2, SEQ ID NO: 46)

In General Formula 2,

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid or serine;

X17 is lysine or arginine;

X20 is glutamine or lysine;

X21 is aspartic acid or glutamic acid;

X24 is valine or glutamine; and

X30 is cysteine or is absent,

wherein, among the peptides including the amino acid sequence of GeneralFormula 2, the peptides corresponding to SEQ ID NOS: 14, 19, 20, 25, 27,31, and 33 may be excluded.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 2 is characterized in that the aminoacid pair of X16 and X20 is substituted with glutamic acid or lysine,which is capable of forming a ring.

In still another specific embodiment, the peptide including the aminoacid sequence of General Formula 2 is characterized in that theC-terminus of the peptide is amidated.

In still another specific embodiment, the peptide is characterized inthat it is a glucagon derivative capable of activating a glucagonreceptor.

In still another specific embodiment, the peptide is characterized inthat it includes an amino acid sequence selected from the groupconsisting of SEQ ID NOS: 12, 13, 15, and 36 to 44.

In still another specific embodiment, the peptide is characterized inthat it includes the amino acid sequence of SEQ ID NO: 12.

In still another aspect, the present invention provides an isolatedpolynucleotide encoding the glucagon derivative, a vector including thepolynucleotide, and an isolated cell including the polynucleotide or thevector.

In still another aspect, the present invention provides an isolatedconjugate in which a glucagon derivative and a biocompatible materialcapable of increasing in vivo half-life are linked.

In a specific embodiment, the biocompatible material is characterized inthat the biocompatible material is selected from the group consisting ofpolyethylene glycol, fatty acid, cholesterol, albumin and a fragmentthereof, an albumin-binding material, a polymer of repeating units of aparticular amino acid sequence, an antibody, an antibody fragment, anFcRn-binding material, in vivo connective tissue or a derivativethereof, a nucleotide, fibronectin, transferrin, a saccharide, and apolymer.

In a specific embodiment, the isolated peptide is characterized in thatit is linked to a biocompatible material by a linker selected from thegroup consisting of polyethylene glycol, polypropylene glycol, anethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, abiodegradable polymer such as polylactic acid (PLA) andpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,fatty acid, a polymer, a low molecular weight compound, a nucleotide,and a combination thereof.

In a specific embodiment, the biocompatible material is characterized inthat it is an FcRn-binding material, and the isolated peptide and theinsulinotropic peptide are respectively linked to a biocompatiblematerial by a peptide linker or a non-peptide linker selected from thegroup consisting of polyethylene glycol, polypropylene glycol, anethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,polyvinyl alcohol, a polysaccharide, polyvinyl ethyl ether, dextran, abiodegradable polymer such as polylactic acid (PLA) orpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,and a combination thereof.

In a specific embodiment, the FcRn-binding material is characterized inthat it is a polypeptide including an immunoglobulin Fc region.

In still another aspect, the present invention provides a compositionincluding the glucagon derivative or the isolated conjugate.

In a specific embodiment, the composition is characterized in that it isa pharmaceutical composition for treating or preventing hypoglycemia ormetabolic syndrome.

In still another aspect, the present invention provides a method forpreventing or treating hypoglycemia or metabolic syndrome includingadministering the composition to the subject in need thereof.

In still another aspect, the present invention provides use of theglucagon derivative or the isolated conjugate or the composition in thepreparation of a medicament (or a pharmaceutical composition) forpreventing or treating hypoglycemia or metabolic syndrome.

Advantageous Effects

The glucagon derivatives of the present invention have improved physicalproperties compared to that of native glucagon and thus can beeffectively used as a therapeutic agent for treating hypoglycemia byimproving the compliance of patients. Additionally, the glucagonderivatives of the present invention can be effectively used for theprevention and treatment of hypoglycemia and metabolic syndrome such asobesity, diabetes, and nonalcoholic steatohepatitis (NASH).

DESCRIPTION OF DRAWINGS

FIG. 1 shows a graph illustrating the changes in body weight of obesityanimal models (rats), which were prepared by high-fat diet, during asingle or combined administration of a long-acting insulinotropicpeptide conjugate (named as a long-acting exendin-4 derivative) and along-acting glucagon derivative conjugate (named as a long-actingderivative of SEQ ID NO: 12) with an adjusted dose to the rats, at 3-dayintervals for 15 days.

FIG. 2 shows a result illustrating the amount of mesenteric fat ofobesity animal models (rats), which were prepared by high-fat diet,measured after a single or combined administration of a long-actinginsulinotropic peptide conjugate (named as a long-acting exendin-4derivative) and a long-acting glucagon derivative conjugate (named as along-acting derivative of SEQ ID NO: 12) with an adjusted dose to therats for 15 days (*p<0.05, **p<0.01 vs. vehicle by ANOVA test).

FIG. 3 shows a result illustrating the difference in liver weight ofobesity animal models (rats), which were prepared by high-fat diet,measured after a single or combined administration of a long-actinginsulinotropic peptide conjugate (named as a long-acting exendin-4derivative) and a long-acting glucagon derivative conjugate (named as along-acting derivative of SEQ ID NO: 12) with an adjusted dose to therats for 15 days (***p<0.01, ***p<0.001 vs. vehicle by ANOVA test).

FIG. 4 shows a graph illustrating the changes in body weight (BW) ofobesity animal models (mice), which were prepared by high-fat diet,after a single or combined administration of a long-actinginsulinotropic peptide conjugate (named as a long-acting exendin-4derivative) and a long-acting glucagon derivative conjugate (named as along-acting derivative of SEQ ID NO: 20) with an adjusted dose to therats for 22 days.

FIG. 5 shows a result illustrating the changes in cholesterol content inblood of obesity animal models (mice), which were prepared by high-fatdiet, after a single or combined administration of a long-actinginsulinotropic peptide conjugate (named as a long-acting exendin-4derivative) and a long-acting glucagon derivative conjugate (named as along-acting derivative of SEQ ID NO: 20) with an adjusted dose to therats for 22 days.

BEST MODE

The specific details of the present invention may be explained asfollows. In particular, the explanations and embodiments disclosed inthe present invention may be applied to other explanations andembodiments, respectively. That is, all combinations of various elementsdisclosed in the present invention belong to the scope of the presentinvention. Additionally, the scope of the present invention should notbe limited by the specific descriptions described herein below.

Throughout the disclosure of the present invention, not only theconventional 1-letter codes and 3-letter codes for amino acids presentin nature but also the 3-letter codes, such as Aib (α-aminoisobutyricacid), Sar(N-methylglycine) generally used for other amino acids, areused. Additionally, the amino acids mentioned in abbreviation in thepresent disclosure are described according to the IUPAC-IUBNomenclature.

alanine A

arginine R

asparagine N

aspartic acid D

cysteine C

glutamic acid E

glutamine Q

glycine G

histidine H

isoleucine I

leucine L

lysine K

methionine M

phenylalanine F

proline P

serine S

threonine T

tryptophan W

tyrosine Y

valine V

An aspect of the present invention provides a composition containing aglucagon derivative and at least one compound or material having atherapeutic activity for metabolic syndrome, and more specifically,provides a pharmaceutical composition for treating or preventingmetabolic syndrome containing a glucagon derivative and at least onecompound or material having a therapeutic activity for metabolicsyndrome.

The glucagon derivative according to the present invention includes apeptide having at least one difference in the amino acid sequencecompared to native glucagon, a peptide in which the sequence of nativeglucagon is modified by modifying native glucagon, and a native glucagonmimetic that can activate glucagon receptors like native glucagon.

Such a glucagon derivative may be one having improved physicalproperties by having an altered pI relative to native glucagon.Additionally, the glucagon derivative may be one with improvedsolubility while maintaining the activity of activating glucagonreceptors, but is not limited thereto.

Additionally, the glucagon derivative may be a non-naturally occurringglucagon.

In particular, native glucagon may have the following amino acidsequence:

(SEQ ID NO: 1) His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln- Trp-Leu-Met-Asn-Thr

As used herein, the term “pI” or “isoelectric point” refers to the pHvalue at which a macromolecule such as a polypeptide has no net charge(0). In the case of a polypeptide with various charged functionalgroups, the net charge of the total polypeptide is “0” at a point wherethe pH value is the same as that of the pI. The net charge of thepolypeptide at a pH higher than the pI will be negative while the netcharge of the polypeptide at a pH lower than the pI will be positive.

The pI values may be determined on an immobilized pH gradient gelconsisting of polyacrylamide, starch, or agarose by isoelectricelectrophoresis, or may be estimated, for example, from an amino acidsequence using a pI/MW tool (expasy.org; Gasteiger et al., 2003) in anExPASy server.

As used herein, the term “altered pI” refers to a pI which is differentfrom that of native glucagon due to the substitution of a part of theamino acid sequence of native glucagon with an amino acid residue havinga negative charge or a positive charge, i.e., a reduced or increased pIvalue. The peptide with such an altered pI can exhibit improvedsolubility and high stability at a neutral pH as a glucagon derivative.

More specifically, the glucagon derivative may have an altered pI value,not the pI value (6.8) of native glucagon, and even more specifically, apI value of less than 6.8, more specifically, 6.7 or less, morespecifically 6.5 or less, and additionally, a pI value exceeding 6.8, 7or higher, more specifically, 7.5 or higher, but is not limited thereto,and any pI value different from that of native glucagon will belong tothe scope of the present invention. In particular, when the pI value isdifferent from that of native glucagon and thus exhibits an improvedsolubility at a neutral pH compared to that of native glucagon thusshowing a low level of aggregation, it will particularly belong to thescope of the present invention.

More specifically, the glucagon derivative may have a pI value of from 4to 6.5 and/or from 7 to 9.5, specifically from 7.5 to 9.5, and morespecifically, from 8.0 to 9.3, but the pI value is not limited thereto.In this case, due to the lower or higher pI value compared to that ofnative glucagon, an improved solubility and high stability at a neutralpH compared to that of native glucagon can be exhibited.

Specifically, a derivative of native glucagon may be modified by any onemethod of substitution, addition, deletion, and modification, or acombination thereof in part of the amino acid of native glucagon.

Examples of the glucagon derivatives prepared by a combination of theabove methods include a peptide which differs in at least one amino acidresidue of the amino acid sequence compared to that of native glucagonand in which the N-terminal amino acid residue is deaminated, having thefunction of activating a glucagon receptor, but is not limited thereto,and the native glucagon derivatives can be prepared by a combination ofvarious methods for preparing the derivatives.

Additionally, such modification for the preparation of native glucagonderivatives may include all of the modifications using L-type or D-typeamino acids, and/or non-native type amino acids; and/or a modificationof native sequence, for example, modification of a functional group, anintramolecular covalent bonding (e.g., a ring formation between sidechains), methylation, acylation, ubiquitination, phosphorylation,aminohexanation, biotinylation, etc.

Additionally, the modification may also include all those where one ormore amino acids are added to the amino and/or carboxy terminal ofnative glucagon.

During the substitution or addition of amino acids, not only the 20amino acids commonly found in human proteins, but also atypical ornon-naturally occurring amino acids can be used. Commercial sources ofatypical amino acids may include Sigma-Aldrich, ChemPep Inc., andGenzyme Pharmaceuticals. The peptides including these amino acids andatypical peptide sequences may be synthesized and purchased fromcommercial suppliers, e.g., American Peptide Company, Bachem (USA), orAnygen (Korea).

Since glucagon has a pH of about 7, it is insoluble in a solution havinga physiological pH (pH 4 to 8) and tends to precipitate at a neutral pH.In an aqueous solution with a pH of 3 or below, glucagon is dissolved atthe initial stage but precipitates within one hour by forming a gel.Since the gelated glucagon mainly consists of β-sheet fibrils, theadministration of the thus-precipitated glucagon via an injection needleor intravenous injection will block blood vessels, and thus is notsuitable for use as an injection agent. In order to delay theprecipitation process, acidic (pH 2 to 4) formulations are commonlyused, and by doing so, glucagon can be maintained in a relativelynon-aggregated state for a short period of time. However, glucagon canform fibrils very rapidly at a low pH, and thus these acidicformulations must be injected upon preparation.

In this regard, the present inventors have developed glucagonderivatives with extended action profiles by modifying the pI of nativeglucagon via substitution of amino acid residues having negative chargesand positive charges. The glucagon derivatives of the present invention,by having an altered pI compared to that of native glucagon, arecharacterized in having improved solubility and/or high stability at aneutral pH, compared to that of native glucagon.

In a specific embodiment of the present invention, the glucagonderivative may be a peptide which includes the amino acid sequence ofthe following General Formula 1:

X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-W-L-X27-X28-X29-X30  (General Formula 1, SEQ ID NO: 45)

In the above Formula,

X1 is histidine, desamino-histidyl, N-dimethyl-histidyl, β-hydroxyimidazopropionyl, 4-imidazoacetyl, β-carboxy imidazopropionyl,tryptophan, or tyrosine, or is absent;

X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine,glycine, Sar(N-methylglycine), serine, or D-serine;

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid, glutamic acid, or cysteine;

X16 is glutamic acid, aspartic acid, serine, α-methyl-glutamic acid, orcysteine, or is absent;

X17 is aspartic acid, glutamine, glutamic acid, lysine, arginine,serine, cysteine, or valine, or is absent;

X18 is alanine, aspartic acid, glutamic acid, arginine, valine, orcysteine, or is absent;

X19 is alanine, arginine, serine, valine, or cysteine, or is absent;

X20 is lysine, histidine, glutamine, aspartic acid, lysine, arginine,α-methyl-glutamic acid, or cysteine, or is absent;

X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine, or isabsent;

X23 is isoleucine, valine, or arginine, or is absent;

X24 is valine, arginine, alanine, cysteine, glutamic acid, lysine,glutamine, α-methyl-glutamic acid, or leucine, or is absent;

X27 is isoleucine, valine, alanine, lysine, methionine, glutamine, orarginine, or is absent;

X28 is glutamine, lysine, asparagine, or arginine, or is absent;

X29 is lysine, alanine, glycine, or threonine, or is absent; and

X30 is cysteine or is absent;

with the proviso that when the amino acid sequence of General Formula 1is identical to SEQ ID NO: 1, it is excluded.

In the above, when the amino acid sequence of General Formula 1 isidentical to any amino acid sequence selected from the group consistingof SEQ ID NOS: 12, 13, 15, and 36 to 44, and in particular, to the aminoacid sequence any of the amino acid sequences of SEQ ID NOS: 13, 15, 36,and 38 to 43, it may be possible that the peptide may be excluded fromthe scope of the peptides that include the amino acid sequence ofGeneral Formula 1, but is not limited thereto.

More specifically,

in General Formula 1,

X1 is histidine, tryptophan, or tyrosine, or is absent;

X2 is serine or aminoisobutyric acid (Aib);

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine, or cysteine;

X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine,or valine;

X18 is aspartic acid, glutamic acid, arginine, or cysteine;

X19 is alanine or cysteine;

X20 is glutamine, aspartic acid, lysine, or cysteine;

X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine;

X23 is isoleucine, valine, or arginine;

X24 is valine, arginine, alanine, glutamic acid, lysine, glutamine, orleucine;

X27 is isoleucine, valine, alanine, methionine, glutamine, or arginine;

X28 is glutamine, lysine, asparagine, or arginine;

X29 is threonine; and

X30 is cysteine or is absent

with the proviso that when the amino acid sequence of General Formula 1is identical to SEQ ID NO: 1, it is excluded.

For example, the peptide may be one which includes an amino acidsequence selected from the group consisting of SEQ ID NOS: 2 to 44, andspecifically, one which (essentially) consists of an amino acid sequenceselected from the group consisting of SEQ ID NOS: 2 to 44, but is notlimited thereto.

Additionally, although described as “a peptide consisting of aparticular SEQ ID NO” in the present invention, such expression does notexclude a mutation in the peptide that can occur by a meaninglesssequence addition upstream or downstream of the amino acid sequence ofthe corresponding SEQ ID NO, or a naturally-occurring mutation therein,or a silent mutation therein, as long as the peptide having suchmutation has an activity the same as or corresponding to that of thepeptide which consists of an amino acid sequence of the correspondingSEQ ID NO. Even when the sequence addition or a mutation is present, itobviously belongs to the scope of the present invention.

In contrast, in another aspect, when the amino acid sequence of GeneralFormula 1 is identical to the amino acid sequence selected from thegroup consisting of SEQ ID NOS: 12, 13, 15, and 36 to 44, and inparticular, to any of the amino acid sequences of SEQ ID NOS: 13, 15,36, and 38 to 43, the peptide may be possibly excluded from the scope ofthe peptides that include the amino acid sequence of General Formula 1,but is not limited thereto. Those described above may be also applied toother specific embodiments or aspects, but is not limited thereto.

Specifically, in General Formula 1,

X1 is histidine, tryptophan, or tyrosine, or is absent;

X2 is serine or aminoisobutyric acid (Aib);

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X13 is tyrosine or cysteine;

X14 is leucine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine or cysteine;

X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine,or valine;

X18 is aspartic acid, glutamic acid, arginine, or cysteine;

X19 is alanine or cysteine;

X20 is glutamine, aspartic acid, or lysine;

X21 is aspartic acid or glutamic acid;

X23 is valine;

X24 is valine or glutamine;

X27 is isoleucine or methionine;

X28 is asparagine or arginine;

X29 is threonine; and

X30 is cysteine or is absent

with the proviso that when the amino acid sequence of General Formula 1is identical to SEQ ID NO: 1, it is excluded.

For example, the peptide may be one which includes an amino acidsequence selected from the group consisting of SEQ ID NOS: 2 to 13, 15,17, 20 to 24, 26 to 30, and 32 to 44, and specifically, one which(essentially) consists of an amino acid sequence selected from the groupconsisting of SEQ ID NOS: 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to44, but is not limited thereto.

Specifically, in the General Formula 1,

X1 is tyrosine;

X2 is aminoisobutyric acid;

X7 is threonine;

X10 is tyrosine;

X12 is lysine;

X13 is tyrosine;

X14 is leucine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid, serine, or cysteine;

X17 is lysine or arginine;

X18 is arginine;

X19 is alanine;

X20 is glutamine, cysteine, or lysine;

X21 is aspartic acid, cysteine, valine, or glutamic acid;

X23 is valine;

X24 is valine or arginine;

X27 is methionine;

X28 is asparagine or arginine;

X29 is threonine; and

X30 is absent.

For example, the peptide may be one which includes an amino acidsequence selected from the group consisting of SEQ ID NOS: 14, 16, 18,19, 25 and 31, and specifically, one which (essentially) consists of anamino acid sequence selected from the group consisting of SEQ ID NOS:14, 16, 18, 19, 25 and 31, but is not limited thereto.

More specifically, the peptide may be a peptide which includes the aminoacid sequence of the following General Formula 2:

Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-M-N-T-X30  (GeneralFormula 2, SEQ ID NO: 46)

In General Formula 2,

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid or serine;

X17 is lysine or arginine;

X20 is glutamine or lysine;

X21 is aspartic acid or glutamic acid;

X24 is valine or glutamine; and

X30 is cysteine or is absent,

with the proviso that when the amino acid sequence of General Formula 2is identical to any one of SEQ ID NOS: 14, 19, 20, 25, 27, 31, and 33,it may be excluded, but it is not limited thereto.

For example, the peptide may be one which includes an amino acidsequence selected from the group consisting of SEQ ID NOS: 12, 13, 15,and 36 to 44, and specifically, one which (essentially) consists of anamino acid sequence selected from the group consisting of SEQ ID NOS:12, 13, 15, and 36 to 44, but is not limited thereto. More specifically,the peptide may be one which includes an amino acid sequence of SEQ IDNO: 12 or SEQ ID NO: 20, or (essentially) consists of the correspondingamino acid sequence, but is not limited thereto.

Additionally, the peptide including the amino acid sequence of GeneralFormula 1 or General Formula 2 may be one in which at least one aminoacid pair among the amino acid pairs of X10 and X14, X12 and X16, X16and X20, X17 and X21, X20 and X24, and X24 and X28 in General Formula 1or General Formula 2 may be substituted with glutamic acid or lysine,which is capable of forming a ring, respectively, but is not limitedthereto.

More specifically, the peptide including the amino acid sequence ofGeneral Formula 1 or General Formula 2 may be one in which the aminoacid pair of X12 and X16 or the amino acid pair of X16 and X20 isrespectively substituted with glutamic acid or lysine, which is capableof forming a ring.

More specifically, at least one amino acid pair among the amino acidpairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 andX24, and X24 and X28 may be one which forms a ring (e.g., a lactamring), but is not limited thereto.

In particular, the peptide may be modified in its amino terminus orcarboxy terminus or protected by various organic groups for protectingthe peptide from protein-cleaving enzymes in vivo while increasing itsstability, for example, one in which its C-terminus is amidated.

Additionally, the peptide of the present invention may be synthesized bya method well known in the art, according to its length, e.g., by anautomatic peptide synthesizer, and may be produced by geneticengineering technology.

Specifically, the peptide of the present invention may be prepared by astandard synthesis method, a recombinant expression system, or any othermethod known in the art. Accordingly, the glucagon derivative of thepresent invention may be synthesized by various methods including, forexample, the methods described below:

(a) a method of synthesizing a peptide by a solid-phase or liquid-phasemethod stepwise or by fragment assembly, followed by isolation andpurification of the final peptide product; or

(b) a method of expressing a nucleic acid construct encoding a peptidein a host cell and recovering the expression product from the host cellculture; or

(c) a method of performing an in vitro cell-free expression of a nucleicacid construct encoding a peptide and recovering the expression producttherefrom; or

a method of obtaining peptide fragments by any combination of themethods (a), (b), and (c), obtaining the peptide by linking the peptidefragments, and then recovering the peptide.

In a more specific example, a desired glucagon derivative may beproduced by genetic manipulation, which includes preparing a fusion geneencoding a fusion protein, including a fusion partner and a glucagonderivative, transforming the resultant into a host cell, expressing inthe form of a fusion protein, and cleaving the glucagon derivative fromthe fusion protein using a protease or a compound which is capable ofprotein cleavage followed by separation. For this purpose, for example,an amino acid residue-encoding DNA sequence that can be cleaved by aprotease such as Factor Xa or enterokinase, CNBr, or a compound such ashydroxylamine, may be inserted between the fusion partner and apolynucleotide encoding a glucagon derivative.

In a specific embodiment of the present invention, it was confirmed thatthe peptide of the present invention has a different pI compared to thatof native glucagon (see Table 1). As a result, the peptide of thepresent invention has improved solubility and higher stability at aneutral pH. Accordingly, the peptide of the present invention canincrease patient compliance when used as a hypoglycemic agent and isalso suitable for combined administration of the peptide with otheranti-obesity agents, and thus can be effectively used for the preventionand treatment of hypoglycemia and obesity.

In this regard, the peptide of the present invention can provide anattractive therapeutic selection regarding hypoglycemia, obesity, orassociated diseases thereof.

For example, the peptide of the present invention is a major insulinresponse-controlling hormone, and can be effectively used for thetreatment of severe hypoglycemia in diabetic patients.

Additionally, the peptide of the present invention may be used as apharmaceutical medicament not only for preventing body weight increase,promotion of body weight decrease, reduction of overweight, and obesityincluding morbid obesity (e.g., by controlling appetite, ingestion, foodintake, calorie intake, and/or energy consumption), but also fortreating obesity-related inflammation, obesity-related gallbladderdisease, and obesity-induced sleep apnea, but is not limited thereto,and may be used for treating the associated diseases or healthconditions thereof.

The peptide of the present invention may also be used for treatingmetabolic syndrome other than obesity, i.e., obesity-related diseasessuch as impaired glucose tolerance, hypercholesterolemia, dyslipidemia,obesity, diabetes, hypertension, nonalcoholic steatohepatitis(nonalcoholic steatohepatitis, NASH), atherosclerosis caused bydyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease,stroke, hypoglycemia, etc. However, the effects of the peptide accordingto the present invention may be mediated entirely or partially by thebody weight-related effects described above or may be independent of thesame.

Examples of the compound or material having a therapeutic activity formetabolic syndrome to be included in the combined administration or thecomposition of the present invention may include an insulinotropicpeptide, a glucagon like peptide-1 (GLP-1) receptor agonist, a leptinreceptor agonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, a Y5receptor antagonist, a melanin-concentrating hormone (MCH) receptorantagonist, a Y2/4 receptor agonist, a melanocortin 3/4 (MC 3/4)receptor agonist, a gastric/pancreatic lipase inhibitor, an agonist of5-hydroxytryptamine receptor 2C (5HT2C), a β3A receptor agonist, anamylin receptor agonist, a ghrelin antagonist, a ghrelin receptorantagonist, a peroxisome proliferator-activated receptor alpha (PPARα)agonist, a peroxisome proliferator-activated receptor delta (PPARδ)agonist, a Farnesoid X receptor (FXR) agonist, an acetyl-CoA carboxylaseinhibitor, a peptide YY, cholecystokinin (CCK), xenin, glicentin,obestatin, secretin, nesfatin, insulin, and a glucose-dependentinsulinotropic peptide (GIP), but is not limited thereto. Additionally,all medicaments which are effective for obesity treatment and themedicaments capable of inhibiting hepatic inflammation and fibrosis maybe included.

Specifically, the insulinotropic peptide may be selected from the groupconsisting of GLP-1, exendin-3, exendin-4, an agonist thereof, aderivative thereof, a fragment thereof, a variant thereof, and acombination thereof.

More specifically, the insulinotropic peptide may be an insulinotropicpeptide derivative in which the N-terminal histidine of theinsulinotropic peptide is substituted with one selected from the groupconsisting of desamino-histidyl, N-dimethyl-histidyl, β-hydroxyimidazopropionyl, 4-imidazoacetyl, and β-carboxy imidazopropionyl, butis not limited thereto.

More specifically, the insulinotropic peptide may be selected from thegroup consisting of a native exendin-4; an exendin-4 derivative in whichthe N-terminal amine group of exendin-4 is deleted; an exendin-4derivative in which the N-terminal amine group of exendin-4 issubstituted with a hydroxyl group; an exendin-4 derivative in which theN-terminal amine group of exendin-4 is modified with a dimethyl group;an exendin-4 derivative in which the α-carbon of the 1st amino acid ofexendin-4, histidine, is deleted; an exendin-4 derivative in which the12^(th) amino acid of exendin-4, lysine, is substituted with serine, andan exendin-4 derivative in which the 12^(th) amino acid of exendin-4,lysine, is substituted with arginine, but is not limited thereto.

Meanwhile, as an example of the insulinotropic peptide or a long-actingconjugate thereof, the entire disclosure of U.S. Patent ApplicationPublication No. 2010-0105877 is enclosed in the present invention as areference.

In a more specific embodiment, a glucagon derivative, for example, apeptide including the amino acid sequence of General Formula 1 orGeneral Formula 2, may be in the form of a long-acting conjugate towhich a biocompatible material capable of increasing in vivo half-lifeis linked, but is not limited thereto. The biocompatible material may beinterchangeably used with a carrier.

Additionally, the insulinotropic peptide may also be in the form of along-acting conjugate to which a biocompatible material capable ofincreasing in vivo half-life is linked, but is not limited thereto.

In a specific embodiment of the present invention, the duration ofefficacy of the above conjugate increases compared to native glucagon ora glucagon derivative thereof, to which a carrier is not linked. In thepresent invention, the protein conjugate is called “a long-actingconjugate”.

Examples of the biocompatible material may include polyethylene glycol,fatty acid, cholesterol, albumin and a fragment thereof, analbumin-binding material, a polymer of repeating units of a particularamino acid sequence, an antibody, an antibody fragment, an FcRn-bindingmaterial, in vivo connective tissue or a derivative thereof, anucleotide, fibronectin, transferrin, a saccharide, and a polymer, butare not limited thereto. For example, at least one amino acid side chainwithin the peptide of the present invention may be attached to thebiocompatible material in order to increase in vivo solubility and/orhalf-life, and/or increase bioavailability thereof. These modificationsare known to reduce the clearance of therapeutic proteins and peptides.

For the biocompatible polymer, soluble (amphipathic or hydrophilic),non-toxic, and pharmaceutically inert polymers are appropriate, and forexample, they may include PEG, homopolymers or copolymers of PEG,monomethyl-substituted polymers (mPEG), and poly-amino acids such aspoly-lysine, poly-aspartic acid, and poly-glutamic acid, but are notlimited thereto.

It is a known fact to a skilled person in the art that the thus-modifiedglucagon derivative would have a superior therapeutic effect compared tonative glucagon. Accordingly, the variants of the glucagon derivative asdescribed above also belong to the scope of the present invention.

In a more specific embodiment, the glucagon derivative, for example, thepeptide which includes the amino acid sequence of General Formula 1 orGeneral Formula 2, and the insulinotropic peptide may be respectivelylinked to a biocompatible material by a linker selected from the groupconsisting of polyethylene glycol, polypropylene glycol, an ethyleneglycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinylalcohol, a polysaccharide, dextran, polyvinyl ethyl ether, abiodegradable polymer such as polylactic acid (PLA) andpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,fatty acid, a polymer, a low molecular weight compound, a nucleotide,and a combination thereof, but is not limited thereto.

In an even more specific embodiment, the biocompatible material may bean FcRn-binding material, and the glucagon derivative, for example, thepeptide which includes the amino acid sequence of General Formula 1 orGeneral Formula 2, and the insulinotropic peptide may be respectivelylinked to a biocompatible material by a peptide linker or a non-peptidelinker, but is not limited thereto.

As a specific example, the FcRn-binding material may be a polypeptideincluding an immunoglobulin Fc region.

As used herein, “non-peptide linker” includes a biocompatible polymer towhich at least two repeating units are linked. The repeating units arelinked with each other by a random covalent bond instead of a peptidebond. The non-peptide linker may be one constitution that establishes amoiety of a long-acting conjugate of the present invention.

As used herein, the term “non-peptide linker” may be usedinterchangeably with “non-peptide polymer”.

Additionally, in a specific embodiment, the conjugate may be one inwhich the protein drug is covalently linked to the immunoglobulin Fcregion by a non-peptide linker including a reactive group, which can belinked to the immunoglobulin Fc region and a protein drug on both endsof the conjugate.

Although not particularly limited, the non-peptide linker may be oneselected from the group consisting of polyethylene glycol, polypropyleneglycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylatedpolyol, polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethylether, a biodegradable polymer such as polylactic acid (PLA) andpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,a polysaccharide, and a combination thereof. In a more specificembodiment, the non-peptide polymer may be polyethylene glycol, but isnot limited thereto. Additionally, the derivatives which are alreadyknown in the art and the derivatives which can be easily prepared at thelevel of the technology in the art belong to the scope of the presentinvention.

The non-peptide linker to be used in the present invention may be anypolymer which has a resistance to in vivo proteases, without limitation.The molecular weight of the non-peptide polymer may be in the range of 1kDa to 100 kDa, and specifically, 1 kDa to 20 kDa, but is not limitedthereto. Additionally, the non-peptide linker of the present invention,which is linked to the polypeptide including the immunoglobulin Fcregion, may include not only a single kind of a polymer but also acombination of different kinds of polymers.

In a specific embodiment, both ends of the non-peptide linker may berespectively linked to an amine group or a thiol group of a peptide,which comprises the amino acid sequence of General Formula 1, or aninsulinotropic peptide, and a biocompatible material.

Specifically, the non-peptide polymer may include a reactive group onboth ends, respectively, which can be linked to an immunoglobulin Fcfragment and, a glucagon derivative or an insulinotropic peptide; andspecifically, a reactive group which can be linked to an amine group ofN-terminus or lysine, or a thiol group of cystenine of the glucagonderivative or the insulinotropic peptide, or the immunoglobulin Fcfragment.

Additionally, the reactive group of the non-peptide polymer that can belinked to the immunoglobulin Fc region, the glucagon derivative, and theinsulinotropic peptide may be selected from the group consisting of analdehyde group, a maleimide group, and a succinimide derivative, but isnot limited thereto.

In the above, examples of the aldehyde group may include apropionaldehyde group or a butyraldehyde group, but are not limitedthereto.

In the above, as a succinimide derivative, succinimidyl valerate,succinimidyl methylbutanoate, succinimidyl methylpropionate,succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccinimide,hydroxy succinimidyl, succinimidyl carboxymethyl, or succinimidylcarbonate may be used, but is not limited thereto.

Additionally, the final product produced through reductive alkylationvia an aldehyde bond is more stable than that linked by an amide bond.The aldehyde reactive group selectively reacts with a N-terminus at alow pH condition while it can form a covalent bond with a lysine residueat high pH, e.g., pH 9.0.

The reactive groups at both ends of the non-peptide linker may be thesame as or different from each other, for example, a maleimide reactivegroup may be provided at one end and an aldehyde group, apropionaldehyde group, or a butyraldehyde group may be provided at theother end. However, if an immunoglobulin Fc region and a glucagonderivative or an insulinotropic peptide can be conjugated at each end ofthe non-peptide linker, it is not particularly limited.

For example, the non-peptide polymer may possess a maleimide group atone end and an aldehyde group, a propionaldehyde group, or abutyraldehyde group at the other end.

When a polyethylene glycol having a reactive hydroxy group at both endsthereof is used as the non-peptide polymer, the hydroxy group may beactivated to various reactive groups by known chemical reactions, or apolyethylene glycol having a commercially available modified reactivegroup may be used so as to prepare the long-acting protein conjugate ofthe present invention.

In a specific embodiment, the non-peptide polymer may be one which canbe linked to a cysteine residue of a glucagon derivative, and morespecifically, to the —SH group of cysteine, but is not limited thereto.

In a specific embodiment, the conjugate may be one in which a peptideincluding the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 20 islinked to the immunoglobulin Fc region by a non-peptide polymer, and inparticular, the non-peptide polymer may be one which is linked to thecysteine residue located on the 30^(th) of the amino acid sequence ofSEQ ID NO: 12 or the cysteine residue located on the 17^(th) of theamino acid sequence of SEQ ID NO: 20, but is not limited thereto.

When maleimide-PEG-aldehyde is used, the maleimide group may be linkedto the —SH group of the glucagon derivative by a thioether bond and thealdehyde group may be linked to the —NH₂ of the immunoglobulin Fcthrough reductive alkylation, but is not limited thereto and the aboveis merely an embodiment.

In the present invention, “immunoglobulin Fc region” refers to a regionincluding the heavy chain constant region 2 (CH2) and/or the heavy chainconstant region 3 (CH3), excluding the heavy chain and light chainvariable regions of an immunoglobulin. The immunoglobulin Fc region maybe one constitution that establishes a moiety of a protein conjugate ofthe present invention.

The immunoglobulin Fc region may include a hinge region in the heavychain constant region, but is not limited thereto. Additionally, theimmunoglobulin Fc region of the present invention may be an extended Fcregion including a part or the entirety of the heavy chain constantregion 1 (CH1) and/or the light chain constant region 1 (CL1), excludingthe heavy chain and the light chain variable regions of theimmunoglobulin, as long as the immunoglobulin Fc region has an effectsubstantially the same as or improved compared to the native type.Additionally, the immunoglobulin Fc region of the present invention maybe a region in which a fairly long part of the amino acid sequencecorresponding to CH2 and/or CH3 is removed.

For example, the immunoglobulin Fc region of the present invention maybe 1) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain; 2) aCH1 domain and a CH2 domain; 3) a CH1 domain and a CH3 domain; 4) a CH2domain and a CH3 domain; 5) a combination between one or two or moredomains among a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domainand an immunoglobulin hinge region (or a part of the hinge region); and6) a dimer between each domain of the heavy chain constant region andthe light chain constant region, but is not limited thereto.

Additionally, in a specific embodiment, the immunoglobulin Fc region maybe in a dimeric form, and one molecule of a glucagon derivative orinsulinotropic peptide may be covalently linked to a Fc region in adimeric form, and in particular, the immunoglobulin Fc and the glucagonderivative or the insulinotropic peptide may be interlinked by anon-peptide polymer. Furthermore, two molecules of the glucagonderivative or insulinotropic peptide may be possibly conjugated in asymmetrical manner to a single Fc region in a dimeric form. Inparticular, the immunoglobulin Fc and the glucagon derivative or theinsulinotropic peptide may be interlinked by a non-peptide linker, butare not limited to the embodiment described above.

Additionally, the immunoglobulin Fc region of the present invention notonly includes a native amino acid sequence but also a sequencederivative thereof. An amino acid sequence derivative refers to an aminoacid sequence which has a difference in at least one amino acid residuedue to deletion, insertion, non-conservative or conservativesubstitution, or a combination thereof.

For example, the amino acid residues at positions 214 to 238, 297 to299, 318 to 322, or 327 to 331, which are known to be in the binding ofan immunoglobulin Fc, may be used as suitable sites for modification.

Additionally, other various derivatives are possible, including one thathas a deletion of a region capable of forming a disulfide bond, or adeletion of some amino acid residues at the N-terminus of native Fc oran addition of a methionine residue at the N-terminus of native Fc.Further, to remove effector functions, a deletion may occur in acomplement-binding site, such as a C1q-binding site and an antibodydependent cell mediated cytotoxicity (ADCC) site. Techniques ofpreparing such sequence derivatives of the immunoglobulin Fc region aredisclosed in International Patent Publication Nos. WO 97/34631, WO96/32478, etc.

Amino acid exchanges in proteins and peptides, which do not generallyalter the activity of the proteins or peptides, are known in the art (H.Neurath, R. L. Hill, The Proteins, Academic Press, New York, 1979). Themost commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu,Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro,Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly, in bothdirections. In addition, the Fc region may, if necessary, be modified byphosphorylation, sulfation, acrylation, glycosylation, methylation,famesylation, acetylation, amidation, etc.

The above-described Fc derivatives show biological activity identical tothat of the Fc region of the present invention and have improvedstructural stability against heat, pH, etc.

Further, the immunoglobulin Fc region may be obtained from native formsisolated in vivo from humans or animals such as cows, goats, pigs, mice,rabbits, hamsters, rats, guinea pigs, etc., or may be recombinants orderivatives thereof, obtained from transformed animal cells ormicroorganisms. Herein, the Fc region may be obtained from a nativeimmunoglobulin by isolating a whole immunoglobulin from a living humanor animal body and treating the isolated immunoglobulin with protease.When the whole immunoglobulin is treated with papain, it is cleaved intoFab and Fc regions, whereas when the whole immunoglobulin is treatedwith pepsin, it is cleaved into pF′c and F(ab)₂ fragments. Fc or pF′ccan be isolated using size exclusion chromatography, etc. In a morespecific embodiment, a human-derived Fc region is a recombinantimmunoglobulin Fc region obtained from a microorganism.

In addition, the immunoglobulin Fc region may have natural glycans,increased or decreased glycans compared to the natural type, or be in adeglycosylated form. The increase, decrease, or removal of the glycansof the immunoglobulin Fc may be achieved by conventional methods such asa chemical method, an enzymatic method, and a genetic engineering methodusing a microorganism. The immunoglobulin Fc region obtained by removalof glycans from the Fc region shows a significant decrease in bindingaffinity to the C1q part and a decrease or loss in antibody-dependentcytotoxicity or complement-dependent cytotoxicity, and thus it does notinduce unnecessary immune responses in vivo. In this regard, animmunoglobulin Fc region in a deglycosylated or aglycosylatedimmunoglobulin Fc region may be a more suitable form to meet theoriginal object of the present invention as a drug carrier.

As used herein, the term “deglycosylation” refers to enzymaticallyremoving sugar moieties from an Fc region, and the term “aglycosylation”refers to an unglycosylated Fc region produced in prokaryotes, morespecifically, E. coli.

Meanwhile, the immunoglobulin Fc region may be derived from humans orother animals including cows, goats, pigs, mice, rabbits, hamsters,rats, and guinea pigs. In a more specific embodiment, it is derived fromhumans.

In addition, the immunoglobulin (Ig) Fc region may be derived from IgG,IgA, IgD, IgE, IgM, or a combination or hybrid thereof. In a morespecific embodiment, it is derived from IgG or IgM, which are among themost abundant proteins in human blood, and in an even more specificembodiment, it is derived from IgG, which is known to enhance thehalf-lives of ligand-binding proteins. In a yet even more specificembodiment, the immunoglobulin Fc region is an IgG4 Fc region, and inthe most specific embodiment, the IgG4 Fc region is an aglycosylated Fcregion derived from human IgG4, but is not limited thereto.

In particular, as used herein, the term “combination” means thatpolypeptides encoding single-chain immunoglobulin Fc regions of the sameorigin are linked to a single-chain polypeptide of a different origin toform a dimer or multimer. That is, a dimer or multimer may be formedfrom two or more fragments selected from the group consisting of IgG Fc,IgA Fc, IgM Fc, IgD Fc, and IgE Fc fragments.

The composition of the present invention can be used for preventing ortreating hypoglycemia or metabolic syndromes.

As used herein, the term “prevention” refers to all kinds of actionsassociated with the inhibition or delay of the occurrence ofhypoglycemia or metabolic syndrome by the administration of the peptideor the composition, and the term “treatment” refers to all kinds ofactions associated with the improvement or advantageous changes insymptoms of hypoglycemia or metabolic syndrome by the administration ofthe peptide or the composition.

As used herein, the term “administration” refers to an introduction of aparticular material to a patient by an appropriate manner. Thecomposition may be administered by a general route that enables thedelivery of the composition to a target tissue in vivo, for example,intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal,oral, topical, intranasal, intrapulmonary, and intrarectaladministration, but is not particularly limited thereto.

As used herein, the term “metabolic syndrome” refers to a symptom of asingle or complex occurrence of various diseases due to chronicmetabolic disorder, and in particular, examples of metabolic syndromemay include impaired glucose tolerance, hypercholesterolemia,dyslipidemia, obesity, diabetes, hypertension, nonalcoholicsteatohepatitis (NASH), atherosclerosis caused by dyslipidemia,atherosclerosis, arteriosclerosis, coronary heart disease, stroke, etc.,but are not limited thereto.

As used herein, the term “obesity” refers to a medical condition withexcess body fat in the body, and a person having a body mass index (BMI;body mass (kg) divided by the square of the body height (m)) of 25 orhigher is diagnosed as having obesity. Obesity generally occurs due to along-term energy imbalance in which energy intake exceeds energyexpenditure. Obesity is a metabolic disease that affects the entirebody, which increases the risk of diabetes, hyperlipidemia, sexualdysfunction, arthritis, and cardiovascular disease, and in some cases,it is also associated with the occurrence of cancers.

Diabetes may represent “hypoglycemia” as an acute symptom.

As used herein, the term “hypoglycemia” refers to an acute symptom ofdiabetes, in which blood glucose levels are lower than those of normalpeople, and in general, refers to a state when the blood glucose levelsare 50 mg/dL or less. Hypoglycemia is frequently caused when a personwho takes an oral hypoglycemic agent or insulin has eaten less thanusual or has performed activities or exercised more than usual. Inaddition, hypoglycemia may occur due to the use of glucoselevel-lowering drugs, severe physical diseases, deficiency in hormonessuch as adrenocortical hormones and glucagon, tumor in insulin-producingpancreas, autoimmune insulin syndrome, gastrectomy patients, hereditarycarbohydrate metabolism disorder, etc.

Symptoms of hypoglycemia include weakness, trembling, pale skin, coldsweats, dizziness, excitement, anxiety, pounding heart, empty stomach,headache, fatigue, etc. In the case of persistent hypoglycemia, it maylead to convulsion or seizure, and may cause shock and thus fainting.

The pharmaceutical composition of the present invention may contain apharmaceutically acceptable carrier, excipient, or diluent. As usedherein, the term “pharmaceutically acceptable” refers to the propertiesof having a sufficient amount to exhibit a therapeutic effect and notcausing adverse effects, and may be easily determined by a skilledperson in the art based on the factors well known in the medical field,such as the kind of disease, age, body weight, health status, sex, drugsensitivity of a patient, administration route, administration method,administration frequency, duration of treatment, a drug to be mixed oradministered simultaneously in combination, etc.

The pharmaceutical composition of the present invention containing thepeptide of the present invention may further contain a pharmaceuticallyacceptable carrier. The pharmaceutically acceptable carrier may include,for oral administration, a binder, a glidant, a disintegrant, anexcipient, a solubilizing agent, a dispersant, a stabilizing agent, asuspending agent, a coloring agent, a flavoring agent, etc.; forinjections, a buffering agent, a preserving agent, an analgesic, asolubilizing agent, an isotonic agent, a stabilizing agent, etc., whichmay be combined to be used; and for topical administrations, a base, anexcipient, a lubricant, a preserving agent, etc., although it is notlimited thereto.

The formulation type of the composition according to the presentinvention may be prepared variously by combining with a pharmaceuticallyacceptable carrier as described above. For example, for oraladministration, the composition may be formulated into tablets, troches,capsules, elixirs, suspensions, syrups, wafers, etc. For injections, thecomposition may be formulated into single-dose ampoules or multidosecontainers. The composition may be also formulated into solutions,suspensions, tablets, capsules, and sustained-release formulations.

Meanwhile, examples of suitable carriers, excipients, and diluents mayinclude lactose, dextrose, sucrose, sorbitol, mannitol, xylitol,erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calciumphosphate, calcium silicate, cellulose, methyl cellulose,microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate,mineral oil, etc. Additionally, the composition may further contain afiller, an anti-coagulant, a lubricant, a humectant, a flavoring agent,a preservative, etc.

Additionally, the pharmaceutical composition of the present inventionmay be prepared in any formulation type selected from the groupconsisting of tablets, pills, powders, granules, capsules, suspensions,liquid medicine for internal use, emulsions, syrups, sterile injectionsolutions, non-aqueous solvents, lyophilized formulations, andsuppositories. Additionally, the composition may be formulated into asingle dosage form suitable for the patient's body, and preferably isformulated into a preparation useful for peptide drugs according to thetypical method used in the pharmaceutical field to be administered by anoral or parenteral route, such as through skin, intravenously,intramuscularly, intra-arterially, intramedullarily, intrathecally,intraventricularly, pulmonarily, transdermally, subcutaneously,intraperitoneally, intranasally, intragastrically, topically,sublingually, vaginally, or rectally, but is not limited thereto.

Additionally, the peptide may be used by blending with variouspharmaceutically acceptable carriers such as physiological saline ororganic solvents. In order to increase the stability or absorptivity,carbohydrates such as glucose, sucrose, or dextrans; antioxidants suchas ascorbic acid or glutathione; chelating agents; low molecular weightproteins; or other stabilizers may be used.

The administration dose and frequency of the pharmaceutical compositionof the present invention are determined by the type of activeingredient(s), along with various factors, such as the disease to betreated, administration route, patient's age, sex, and body weight, andseverity of the disease.

The total effective dose of the composition of the present invention maybe administered to a patient in a single dose, or may be administeredfor a long period of time in multiple doses according to a fractionatedtreatment protocol. In the pharmaceutical composition of the presentinvention, the content of active ingredient(s) may vary depending on thedisease severity. Specifically, the preferable total daily dose of thepeptide of the present invention may be approximately 0.0001 μg to 500mg per 1 kg of body weight of a patient. However, the effective dose ofthe peptide is determined considering various factors includingpatient's age, body weight, health conditions, sex, disease severity,diet, and excretion rate, in addition to administration route andtreatment frequency of the pharmaceutical composition. In this regard,those skilled in the art may easily determine the effective dosesuitable for the particular use of the pharmaceutical composition of thepresent invention. The pharmaceutical composition according to thepresent invention is not particularly limited to the formulation andadministration route and mode, as long as it shows the effects of thepresent invention.

The pharmaceutical composition of the present invention shows excellentin vivo duration of efficacy and titer, and thus the number andfrequency of administration of the pharmaceutical preparation of thepresent invention can be significantly reduced.

In particular, since the pharmaceutical composition of the presentinvention contains, as an active ingredient, a glucagon derivativehaving an altered pI different from that of native glucagon, it showsimproved solubility and high stability according to the pH of a givensolution, and thus the pharmaceutical composition of the presentinvention can be effectively used in the preparation of a stableglucagon formulation for treating hypoglycemia or obesity.

In another aspect, the present invention provides a novel glucagonderivative.

The glucagon derivative is the same as explained above.

More specifically, the derivative is characterized in that it is anisolated peptide including the amino acid sequence of the followingGeneral Formula 2.

Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-M-N-T-X30  (GeneralFormula 2, SEQ ID NO: 46)

In General Formula 2,

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid or serine;

X17 is lysine or arginine;

X20 is glutamine or lysine;

X21 is aspartic acid or glutamic acid;

X24 is valine or glutamine; and

X30 is cysteine, or is absent,

with the proviso that when the amino acid sequence of General Formula 2is identical to any one of SEQ ID NOS: 14, 19, 20, 25, 27, 31, and 33,it may be excluded.

More specifically, the amino acid pair of X16 and X20 of General Formula2 may be one substituted with glutamic acid or lysine, respectively,which is capable of forming a ring, thereby forming a ring (e.g., alactam ring) by the amino acid pair of X16 and X20, but is not limitedthereto.

Additionally, the C-terminus of the peptide including the amino acidsequence of General Formula 2 may be amidated, but is not limitedthereto.

Additionally, the peptide may be a glucagon derivative capable ofactivating a glucagon receptor, but is not limited thereto.

More specifically, the peptide may include an amino acid sequenceselected from the group consisting of SEQ ID NOS: 12, 13, 15, and 36 to44, but is not limited thereto.

In still another aspect, the present invention provides an isolatedpolynucleotide encoding the glucagon derivative, a vector including thepolynucleotide, and an isolated cell including the polynucleotide or thevector.

The glucagon derivative is the same as explained above.

Additionally, the isolated polynucleotide encoding the glucagonderivative includes within the scope of the present invention apolynucleotide sequence having a homology of 75% or higher, specifically85% or higher, more specifically 90% or higher, and even morespecifically 95% or higher, to the corresponding sequence.

As used herein, the term “homology” indicates sequence similarity with awild-type amino acid sequence or wild-type nucleotide sequence, and thehomology comparison may be done with the naked eye or using acommercially available comparison program. Using a commerciallyavailable computer program, the homology between two or more sequencesmay be expressed as a percentage (%), and the homology (%) betweenadjacent sequences may be calculated.

As used herein, the term “recombinant vector” refers to a DNA constructincluding the sequence of a polynucleotide encoding a target peptide,e.g., a glucagon derivative, which is operably linked to an appropriateregulatory sequence to enable the expression of the target peptide,e.g., a glucagon derivative, in a host cell.

The regulatory sequence includes a promoter capable of initiatingtranscription, any operator sequence for the regulation of thetranscription, a sequence encoding an appropriate mRNA ribosome-bindingdomain, and a sequence regulating the termination of transcription andtranslation. The recombinant vector, after being transformed into asuitable host cell, may be replicated or function irrespective of thehost genome, or may be integrated into the host genome itself.

The recombinant vector used in the present invention may not beparticularly limited as long as the vector is replicable in the hostcell, and it may be constructed using any vector known in the art.Examples of the vector conventionally used may include natural orrecombinant plasmids, cosmids, viruses, and bacteriophages. The vectorsto be used in the present invention may be any expression vector knownin the art.

The recombinant vector is used for the transformation of a host cell forproducing glucagon derivatives of the present invention. Additionally,these transformed cells, as a part of the present invention, may be usedfor the amplification of nucleic acid fragments and vectors, or may becultured cells or cell lines used in the recombinant production ofglucagon derivatives of the present invention.

As used herein, the term “transformation” refers to a process ofintroducing a recombinant vector including a polynucleotide encoding atarget protein into a host cell, thereby enabling the expression of theprotein encoded by the polynucleotide in the host cell. For thetransformed polynucleotide, it does not matter whether it is insertedinto the chromosome of a host cell and located thereon or locatedoutside of the chromosome, as long as it can be expressed in the hostcell, and both cases are included.

Additionally, the polynucleotide includes DNA and RNA which encode thetarget protein. The polynucleotide may be inserted in any form insofaras it can be introduced into a host cell and expressed therein. Forexample, the polynucleotide may be introduced into a host cell in theform of an expression cassette, which is a gene construct including allthe essential elements required for self-expression. The expressioncassette may conventionally include a promoter operably linked to thepolynucleotide, a transcription termination signal, a ribosome-bindingdomain, and a translation termination signal. The expression cassettemay be in the form of an expression vector capable of self-replication.Additionally, the polynucleotide may be introduced into a host cell asit is and operably linked to a sequence essential for its expression inthe host cell, but is not limited thereto.

Additionally, as used herein, the term “operably linked” refers to afunctional connection between a promoter sequence, which initiates andmediates the transcription of the polynucleotide encoding the targetpeptide of the present invention, and the above gene sequence.

An appropriate host to be used in the present invention may not beparticularly limited as long as it can express the polynucleotide of thepresent invention. Examples of the appropriate host may include bacteriabelonging to the genus Escherichia such as E. coli; bacteria belongingto the genus Bacillus such as Bacillus subtilis; bacteria belonging tothe genus Pseudomonas such as Pseudomonas putida; yeasts such as Pichiapastoris, Saccharomyces cerevisiae, and Schizosaccharomyces pombe;insect cells such as Spodoptera frugiperda (Sf9), and animal cells suchas CHO, COS, and BSC.

In still another aspect, the present invention provides an isolatedconjugate in which a glucagon derivative and a biocompatible materialwhich is capable of increasing in vivo half-life are linked. Theconjugate may be a long-acting conjugate.

Regarding the glucagon derivative, the biocompatible material, and theconstitution of the conjugate, all those described above are applied.

Specifically, the biocompatible material may be selected from the groupconsisting of polyethylene glycol, fatty acid, cholesterol, albumin anda fragment thereof, an albumin-binding material, a polymer of repeatingunits of a particular amino acid sequence, an antibody, an antibodyfragment, an FcRn-binding material, in vivo connective tissue or aderivative thereof, a nucleotide, fibronectin, transferrin, saccharide,and a polymer, but is not limited thereto.

Additionally, the isolated peptide may be linked to a biocompatiblematerial by a linker selected from the group consisting of polyethyleneglycol, polypropylene glycol, an ethylene glycol-propylene glycolcopolymer, polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide,dextran, polyvinyl ethyl ether, a biodegradable polymer such aspolylactic acid (PLA) and polylactic-glycolic acid (PLGA), lipidpolymer, chitin, hyaluronic acid, fatty acid, a polymer, a low molecularweight compound, a nucleotide, and a combination thereof, but is notlimited thereto.

Additionally, the biocompatible material may be an FcRn-bindingmaterial, and the isolated peptide may be linked to a biocompatiblematerial by a peptide linker or a non-peptide linker selected from thegroup consisting of polyethylene glycol, polypropylene glycol, anethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, abiodegradable polymer such as polylactic acid (PLA) andpolylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,and a combination thereof, but is not limited thereto.

Additionally, the FcRn-binding material may be a polypeptide includingthe immunoglobulin Fc region, but is not limited thereto.

In still another aspect, the present invention provides a compositioncontaining the glucagon derivative or the isolated conjugate.

The glucagon derivative and the isolated conjugate are the same asexplained above.

Specifically, the composition may be a pharmaceutical composition fortreating or preventing hypoglycemia or metabolic syndrome, but is notlimited thereto. The pharmaceutical composition is the same as describedabove.

Additionally, the composition may be a composition containing thepeptide of the amino acid sequence of the following General Formula 2.

Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-M-N-T-X30  (GeneralFormula 2, SEQ ID NO: 46)

In General Formula 2,

X7 is threonine, valine, or cysteine;

X10 is tyrosine or cysteine;

X12 is lysine or cysteine;

X15 is aspartic acid or cysteine;

X16 is glutamic acid or serine;

X17 is lysine or arginine;

X20 is glutamine or lysine;

X21 is aspartic acid or glutamic acid;

X24 is valine or glutamine; and

X30 is cysteine or is absent,

with the proviso that when the amino acid sequence of General Formula 2is identical to any one of SEQ ID NOS: 14, 19, 20, 25, 27, 31, and 33,it may be excluded.

In still another aspect, the present invention provides a method forpreventing or treating hypoglycemia or metabolic syndrome, includingadministering the above composition to a subject.

The composition, hypoglycemia, metabolic syndrome, prevention, andtreatment are the same as explained above.

In the present invention, the term “subject” refers to those suspectedof having hypoglycemia or metabolic syndrome, which means mammalsincluding humans, mice, and livestock having hypoglycemia or metabolicsyndrome or having the risk of hypoglycemia or metabolic syndrome.However, any subject to be treated with the glucagon derivative of thepresent invention or the composition containing the same is includedwithout limitation. Further, the subject suspected of havinghypoglycemia or obesity can be effectively treated by administering withthe pharmaceutical composition containing the glucagon derivative of thepresent invention. The hypoglycemia and obesity are the same asexplained above.

The method of the present invention may include administering thepharmaceutical composition containing the peptide at a pharmaceuticallyeffective amount. The total daily dose should be determined withinappropriate medical judgment by a physician, and administered once orseveral times in divided doses. Regarding the objects of the presentinvention, the specific therapeutically effective dose for anyparticular patient may be preferably applied differently, depending onvarious factors well known in the medical art, including the kind anddegree of the response to be achieved, specific compositions includingwhether other agents are occasionally used therewith or not, thepatient's age, body weight, general health conditions, sex and diet, thetime and route of administration, secretion rate of the composition,duration of treatment, other drugs used in combination or concurrentlywith the composition of the present invention, and like factors wellknown in the medical arts.

In still another aspect, the present invention provides use of theglucagon derivative or the isolated conjugate or the composition in thepreparation of a medicament (or a pharmaceutical composition) forpreventing or treating hypoglycemia or metabolic syndrome.

The glucagon derivative, the isolated conjugate, the composition,hypoglycemia, and metabolic syndrome are the same as explained above.

MODE FOR INVENTION

Hereinafter, the present invention will be described in more detail withreference to the following examples and experimental examples. However,the following examples and experimental examples are provided forillustrative purposes only, and the scope of the present inventionshould not be limited thereto in any manner.

Example 1: Production of Cell Line Showing cAMP Response to Glucagon

PCR was performed using a region corresponding to Open Reading Frame(ORF) in the cDNA (OriGene Technologies, Inc., USA) of human glucagonreceptor gene as a template along with the following forward and reverseprimers (SEQ ID NOS: 47 and 48, respectively), which include each of theEcoRI and XhoI restriction sites.

In particular, PCR was performed for a total of 30 cycles under thefollowing conditions: 95° C. denaturation for 60 sec, annealing at 55°C. for 60 sec, and polymerization at 68° C. for 30 sec. The amplifiedPCR products were subjected to a 1.0% agarose gel electrophoresis and a450 bp band was obtained by elution.

Forward primer (SEQ ID NO: 47): 5′-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3′Reverse primer (SEQ ID NO: 48): 5′-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3′

The PCR product was cloned into a known animal cell expression vector,x0GC/dhfr, to prepare a recombinant vector x0GC/GCGR.

CHO DG44 cell line cultured in DMEM/F12 (10% FBS) medium was transfectedwith the recombinant vector x0GC/GCGR using LIPOFECTAMINE®, and culturedin a selection medium containing G418 (1 mg/mL) and methotraxate (10nM). Single clone cell lines were selected therefrom by a limit dilutiontechnique, and a cell line showing excellent cAMP response to glucagonin a concentration-dependent manner was finally selected therefrom.

Example 2: Synthesis of Glucagon Derivative

In order to prepare glucagon derivatives with improved physicalproperties, the amino acid sequence of native glucagon of SEQ ID NO: 1was substituted with amino acid residues having positive and negativecharges, and thereby glucagon derivatives were synthesized as shown inTable 1 below. The relative in vitro activities described below weremeasured by the method described in Example 4.

TABLE 1 Amino acid sequences of native glucagon and glucagon derivativesIn vitro Activity (Relative Activity SEQ ID of SEQ ID NOPeptide Sequence Ring Formation pI NO: 1, %) SEQ IDHSQGTFTSDYSKYLDSRRAQDF — 6.8 100 NO: 1 VQWLMNT SEQ IDHSQGTFTSDYSKYLDCDRAQDF — 4.56 0.6 NO: 2 VQWLMNT SEQ IDHSQGTFTSDYSKYLDCERAQDF — 4.66 6.1 NO: 3 VQWLMNT SEQ IDHSQGTFTSDYSKYLDSCDAQDF — 4.13 <0.1 NO: 4 VQWLMNT SEQ IDHSQGTFTSDYSKYLDSCEAQDF — 4.22 0.3 NO: 5 VQWLMNT SEQ IDHSQGTFTSDYSKYLDSCEADDF — 4.03 <0.1 NO: 6 VQWLMNT SEQ IDYSQGTFTSDYSKYLDSCEADDF — 3.71 <0.1 NO: 7 VQWLMNT SEQ IDYXQGTFTSDYSKYLDSCDAQDF — 3.77 <0.1 NO: 8 VQWLINT SEQ IDYXQGTFTSDYSKYLDSCDAQDF — 3.77 <0.1 NO: 9 VVWLINT SEQ IDYXQGTFTSDYSKYLDSCDADDF — 3.66 <0.1 NO: 10 VVWLINT SEQ IDYXQGTFTSDYSKYLDEKCAKEF — 4.78 4.6 NO: 11 VQWLMNT SEQ ID YXQGTFTSDYSKYLDE KRA K EF ring formed 6.20 56.3 NO: 12 VQWLMNTC SEQ IDYXQGTFTSDYSCYLDSRRAQDF — 4.43 5.2 NO: 13 VQWLMNT SEQ IDYXQGTFTSDYSKYLDCKRAKEF — 8.12 18.1 NO: 14 VQWLMNT SEQ IDYXQGTFTSDYSKYLCEKRAQDF — 6.11 1.1 NO: 15 VVWLMNT SEQ IDYXQGTFTSDYSKYLDCRRAQVF — 9.11 4.2 NO: 16 VQWLMRT SEQ IDYXQGTFTSDYSKYLDCVRAQDF — 6.03 23.2 NO: 17 VQWLMRT SEQ IDYXQGTFTSDYSKYLDSRRACDF — 8.15 <0.1 NO: 18 RLWLMNT SEQ ID YXQGTFTSDYSKYLCE KRA K EF ring formed 8.12 12.1 NO: 19 VQWLMNT SEQ ID YXQGTFTSDYSKYLD ECRA K EF ring formed 4.78 299.7 NO: 20 VQWLMNT SEQ ID YXQGTFTSDYSKYLD EKCA K EF ring formed 4.78 57.8 NO: 21 VQWLMNT SEQ ID YXQGTFTSDYSKYLD EKRC K EF ring formed 6.20 147.8 NO: 22 VQWLMNT SEQ ID YXQGTFTSDYSKYCD EKRA K EF ring formed 6.20 76.8 NO: 23 VQWLMNT SEQ ID YXQGTFTSDYSKCLD EKRA K EF ring formed 6.21 58.0 NO: 24 VQWLMNT SEQ ID YXQGTFTSDYSKYLD EKRA K CF ring formed 8.12 46.9 NO: 25 VQWLMNT SEQ ID WXQGTFTSDYSKYLD ECRA K DF ring formed 4.68 1.0 NO: 26 VQWLMNT SEQ ID YXQGTFVSDYSKYLD ECRA K DF ring formed 4.68 93.6 NO: 27 VQWLMNT SEQ ID WXQGTFVSDYSKYLD ECRA K D ring formed 4.68 <0.1 NO: 28 FVQWLMNT SEQ ID YXQGTFTSDYSKCLD ERRA K DF ring formed 6.15 61.3 NO: 29 VQWLMNT SEQ ID WXQGTFTSDYSKCLD ERRA K DF ring formed 4.44 0.3 NO: 30 VQWLMNT SEQ ID YXQGTFTSDYSKYLDC KRAK E F ring formed 8.12 6.3 NO: 31 VQWLMNT SEQ ID -SQGTFTSDYSKYLD E CRAK EFV ring formed 4.78 0.7 NO: 32 QWLMNT SEQ ID YXQGTFTSDYSKYLDSRRAQDF —6.04 108.2 NO: 33 VQWLMNT SEQ ID WXQGTFTSDYSKYCD E RRA K EF ring formed6.21 0.2 NO: 34 VQWLMNT SEQ ID YXQGTFTSDYSKYCD E RRA K EF ring formed6.2 17.7 NO: 35 VQWLMNT SEQ ID YXQGTFTSDCSKYLD E RRA K EF ring formed6.21 9.9 NO: 36 VQWLMNT SEQ ID YXQGTFTSDYSKYLD E RRA K EF ring formed6.21 225.5 NO: 37 VQWLMNTC SEQ ID YXQGTFCSDYSKYLD E RRA K EF ring formed6.15 167.3 NO: 38 VQWLMNT SEQ ID YXQGTFVSDCSKYLD E RRA K DF ring formed6.15 3.7 NO: 39 VQWLMNT SEQ ID YXQGTFVSDYSKYLD E RRA K DF ring formed6.15 40.8 NO: 40 VQWLMNTC SEQ ID YXQGTFCSDYSKYLD E RRA K DF ring formed6.03 45.2 NO: 41 VQWLMNT SEQ ID YXQGTFCSDYSKYLDSRRAQDF — 6.03 37.9NO: 42 VQWLMNT SEQ ID YXQGTFTSDCSKYLDSRRAQDF — 6.03 1.6 NO: 43 VQWLMNTSEQ ID YXQGTFTSDYSKYLDSRRAQDF — 6.21 75.4 NO: 44 VQWLMNTC

In the amino acids sequences described in Table 1, the amino acidrepresented by X represents a non-native amino acid, aminoisobutyricacid(Aib), the underlined amino acid residues represent formation of aring, and “-” in the amino acid sequence indicates that no amino acidresidue is present on the corresponding position.

Example 3: Measurement of pI of Glucagon Derivatives

In order to measure the improved physical properties of glucagonderivatives synthesized in Example 2, pI values were calculated based onthe amino acid sequences using the pI/Mw tool (expasy.org; Gasteiger etal., 2003) in the ExPASy server.

As shown in Table 1 above, while the native glucagon of SEQ ID NO: 1 hada pI of 6.8, the some glucagon derivatives according to the presentinvention showed pI values in the range of from about 4 to about 6.Since the glucagon derivatives according to the present invention havepI values lower or more than that of native glucagon, they can exhibitimproved solubility and higher stability at a neutral pH conditioncompared to native glucagon.

Accordingly, when the glucagon derivatives according to the presentinvention are used as a therapeutic agent for treating hypoglycemia,they can improve patient compliance, and are also suitable foradministration in combination with other anti-obesity agents oranti-diabetes agents, and thus the glucagon derivatives of the presentinvention can be effectively used as a therapeutic agent for treatinghypoglycemia and metabolic syndromes including obesity, diabetes,nonalcoholic steatohepatitis (NASH), dyslipidemia, and coronary heartdisease.

Example 4: Measurement of cAMP Activity of Glucagon Derivatives

The activities of the glucagon derivatives synthesized in Example 2 weremeasured in cell lines having the human glucagon receptors produced inExample 1. Specifically, the transfected cell line was subcultured 3 to4 times a week, aliquoted into a 384-well plate in an amount of 6×10³cell lines/well, and cultured for 24 hours. Native glucagon and glucagonderivatives were suspended in Hank's balanced salt solution (HBSS)buffer containing 0.5 mM of 3-isobutyl-1-methylxanthine (IBMX), 0.1%bovine serum albumin (BSA), and 5 mM4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) with theculture cells, at concentrations of 200 nM and 1600 nM, respectively,continuously subjected into a 4-fold dilution 10 times, applied to acAMP assay kit (LANCE cAMP 384 kit, PerkinElmer), and added to thecultured cells, and their fluorescence value was measured. Uponmeasurement, the highest fluorescence value was set at 100% and thenEC₅₀ values of the glucagon derivative were calculated based on the sameand compared with that of native glucagon, respectively. The results areshown in Table 1 above.

Example 5: Preparation of a Conjugate Including a Glucagon Derivativeand an Immunoglobulin Fc (SEQ ID NO: 12 or 20-Immunoglobulin Fc RegionConjugate)

For the pegylation of a 10 kDa PEG having a maleimide group and analdehyde group, respectively, at both ends (named as“maleimide-PEG-aldehyde”, 10 kDa, NOF, Japan) into the cysteine residueof a glucagon derivative (SEQ ID NOS: 12 and 20), the glucagonderivatives and maleimide-PEG-aldehyde were reacted at a molar ratio of1:1 to 5, at a protein concentration of 3 mg/mL to 10 mg/mL at lowtemperature for 1 to 3 hours. In particular, the reaction was conductedin an environment in which 20% to 60% isopropanol was added. Uponcompletion of the reaction, the reactants were applied to SP SEPHAROSE™HP (GE healthcare, USA) to purify the glucagon derivativesmono-pegylated on cysteine.

Then, the purified mono-pegylated glucagon derivatives and animmunoglobulin Fc were reacted at a molar ratio of 1:2 to 10, at aprotein concentration of 10 mg/mL to 50 mg/mL at 4° C. to 8° C. for 12hours to 18 hours. The reaction was conducted in an environment in whichsodium cyanoborohydride (NaCNBH₃) and 10% to 20% isopropanol were addedto 100 mM calcium phosphate buffer (pH 6.0). Upon completion of thereaction, the reactants were applied to the Butyl SEPHAROSE FF™purification column (GE healthcare, USA) and Source ISO purificationcolumn (GE healthcare, USA) to purify the conjugate including theglucagon derivatives and the immunoglobulin Fc.

After preparation, the purity analyzed by reverse phase chromatography,size exclusion chromatography, and ion exchange chromatography was shownto be 95% or higher.

In particular, the conjugate in which the glucagon derivative of SEQ IDNO: 12 and an immunoglobulin Fc were linked by PEG was named as “theconjugate including the glucagon derivative of SEQ ID NO: 12 and animmunoglobulin Fc” or “a long-acting derivative of SEQ ID NO: 12”, andthey can be interchangeably used in the present invention.

In particular, the conjugate in which the glucagon derivative of SEQ IDNO: 20 and an immunoglobulin Fc were linked by PEG was named as “aconjugate including the glucagon derivative of SEQ ID NO: 20 and animmunoglobulin Fc” or “a long-acting derivative of SEQ ID NO: 20”, andthey can be interchangeably used in the present invention.

Example 6: Preparation of a Conjugate Including an Exendin-4 Derivativeand an Immunoglobulin Fc

A 3.4 kDa PEG having a propionaldehyde group at both ends, i.e., 3.4kPropionALD (2) PEG, was reacted with the Lys of CA exendin-4 usingimidazo-acetyl exendin-4 where the alpha carbon of N-terminal histidinewas deleted (CA exendin-4, AP, USA), and then a coupling was conductedbased on the isomer peak at the rearmost part (Lys27) between the twoLys peaks, which is quite reactive and clearly distinguished from theN-terminal isomer.

A peptide and an immunoglobulin Fc were reacted at a molar ratio of 1:8,at the total protein concentration of 60 mg/mL at 4° C. for 20 hours.The reactant was 100 mM K-P (pH 6.0) and 20 mM SCB, a reducing agent,was added. The coupling reactants were purified by passing through withtwo purification columns. First, a large amount of immunoglobulin Fc notinvolved in the coupling reaction was removed using the SOURCE Q™ (XK-16mL, Amersham Biosciences). Upon application of a salt gradient using 1 MNaCl at 20 mM Tris (pH 7.5) results in the immediate elution of theimmunoglobulin Fc, which has a relatively weak binding affinity,followed immediately by the elution of exendin-4-immunoglobulin Fc. Theimmunoglobulin Fc is removed to some extent by the primary purification,however, complete separation was not achieved by ion exchange columnbecause of the small difference in binding affinity between theimmunoglobulin Fc and the exendin-4-immunoglobulin Fc. Accordingly,secondary purification was performed using the hydrophobicity of the twodifferent materials. The sample, which passed through the primarypurification, was bound to the SOURCE ISO™ (HR16 mL, AmershamBiosciences) using 20 mM Tris (pH 7.5) and 1.5 M ammonium sulfate, andwas then eluted while the concentration of ammonium sulfate wasgradually lowered. As a result, the immunoglobulin Fc, which has a weakbinding affinity for the HIC column, was eluted first, followed by theelution of the exendin-4-immunoglobulin Fc sample, which has a strongbinding affinity, to the rear part. The separation was more easilyperformed compared with the ion exchange column due to the largerdifference in hydrophobicity.

Column: SOURCE Q™ (XK 16 mL, Amersham Biosciences)

Flow rate: 2.0 mL/min

Gradient: A0->25% 70 min B (A: 20 mM Tris, pH 7.5, B: A+1 M NaCl)

Column: SOURCE ISO™ (HR 16 mL, Amersham Biosciences)

Flow rate: 7.0 mL/min

Gradient: B 100->0% 60 min B [A: 20 mM Tris (pH 7.5), B: A+1.5 Mammonium sulfate ((NH₄)₂SO₄)]

The thus-prepared conjugate, in which the exendin-4 derivative and theimmunoglobulin Fc region were linked by PEG, was named as “a long-actingexendin-4 derivative”. Also, such term can be interchangeable used with“a long-acting exendin derivative” in the present invention.

Experimental Example 1: Effect of Body Weight Reduction in Rats withHigh Fat Diet-Induced Obesity

In this experiment, high-fat diet-induced obesity rats, which are widelyused as obesity animal models, were used. The body weight of the ratsbefore administration was about 600 g. The rats were housed individuallyduring the experiment and were given ad libitum access to water.Lighting was not provided between 6 AM and 6 PM.

The test groups fed with high-fat diet include: Group 1, with anexcipient (injection once every 3 days)—control group; Group 2, thelong-acting exendin derivative of Example 6 at 3.3 nmol/kg (injectiononce every 3 days); Group 3, the long-acting derivative of SEQ ID NO: 12at 1.6 nmol/kg (injection once every 3 days); Group 4, the long-actingderivative of SEQ ID NO: 12 at 3.3 nmol/kg (injection once every 3days); Group 5, the long-acting derivative of SEQ ID NO: 12 at 6.6nmol/kg (injection once every 3 days); Group 6, the long-acting exendinderivative of Example 6 at 3.3 nmol/kg+the long-acting derivative of SEQID NO: 12 at 1.6 nmol/kg (injection once every 3 days, respectively);Group 7, the long-acting exendin derivative of Example 6 at 3.3nmol/kg+the long-acting derivative of SEQ ID NO: 12 at 3.3 nmol/kg(injection once every 3 days, respectively); Group 8, the long-actingexendin derivative of Example 6 at 3.3 nmol/kg+the long-actingderivative of SEQ ID NO: 12 at 6.6 nmol/kg (injection once every 3 days,respectively); Group 9, a paired-feeding with Group 4; and Group 10, apaired-feeding with Group 7. The experiment was terminated on the15^(th) day, and the changes in body weight of the rats in each groupwere measured at 3-day intervals during the progress of the experiment.Upon termination of the experiment, the amount of mesenteric fat andliver weight were measured by autopsy. Statistical analysis wasperformed to compare between the excipient group (control group) andtest groups by 1-way ANOVA.

As a result of the measurement of changes in body weight, as can beconfirmed in FIG. 1, the groups administered with either the long-actingexendin derivative or the long-acting derivative of SEQ ID NO: 12 aloneshowed a decrease in body weight by −8% and −7% to −22%, compared tothat before administration, whereas in groups with a combinedadministration of the long-acting exendin derivative and the long-actingderivative of SEQ ID NO: 12, the effect of reducing body weight wasimproved further from −22% to −35%.

Additionally, when the effect of a body weight decrease in the groupadministered with the long-acting derivative of SEQ ID NO: 12 alone andthe group administered with the combination of the long-acting exendinderivative and the long-acting derivative of SEQ ID NO: 12 was comparedwith that of the paired feeding group, respectively, a difference ofabout −11% and about −17% was shown, respectively, thus confirming thatthe body weight reducing effect was shown when administered with theglucagon derivative alone or the combined administration, by actionsother than dietary intake.

That is, it was confirmed that the long-acting glucagon derivative ofthe present invention could play an additional role in body weightreduction in addition to the effect of anorexia.

Additionally, as a result of the measurement of the amount of mesentericfat and liver weight, as can be confirmed in FIGS. 2 and 3, the combinedadministration of the long-acting exendin derivative and the long-actingderivative of SEQ ID NO: 12 showed a significant decrease in body fatand also a decrease in the weight of the liver compared to that of thegroup administered with an excipient. In particular, theincrease/decrease of the weight of the liver is generally caused by theincrease/decrease of the fat present in the liver, and the above effectof decrease in the weight of the liver shows the effect of reducing theliver fat. Accordingly, the decrease of the fat in the liver can bemeasured as a method for measuring the therapeutic effect of metabolicsyndrome such as obesity, diabetes, nonalcoholic steatohepatitis, etc.

Experimental Example 2: Effect of Body Weight Reduction in Mice withHigh Fat Diet-Induced Obesity

In this experiment, high-fat diet-induced obesity mice, which are widelyused as obesity animal models, were used. The body weight of the micebefore administration was about 55 g. The mice were housed 7 mice pereach group during the experiment and were given ad libitum access towater. Lighting was not provided between 6 AM and 6 PM.

The test groups fed with high-fat diet include: Group 1, with anexcipient (injection once every 2 days)—control group; Group 2, thelong-acting exendin derivative of Example 6 at 4.3 nmol/kg (injectiononce every 2 days); Group 3, the long-acting derivative of SEQ ID NO: 20at 4.4 nmol/kg (injection once every 2 days); Group 4, the long-actingderivative of SEQ ID NO: 20 at 8.8 nmol/kg (injection once every 2days); Group 5, the long-acting exendin derivative of Example 6 at 4.3nmol/kg+the long-acting derivative of SEQ ID NO: 20 at 4.4 nmol/kg(injection once every 2 days); Group 6, the long-acting exendinderivative of Example 6 at 2.1 nmol/kg+the long-acting derivative of SEQID NO: 20 at 6.6 nmol/kg (injection once every 2 days); and Group 7, thelong-acting exendin derivative of Example 6 at 0.8 nmol/kg+thelong-acting derivative of SEQ ID NO: 20 at 8.0 nmol/kg (injection onceevery 2 days). The experiment was terminated on the 22^(nd) day, and thechanges in body weight of the mice in each group were measured at 2-dayintervals during the progress of the experiment. Upon termination of theexperiment, the weight of the mouse livers was measured by autopsy.

As a result of the measurement of changes in body weight, as can beconfirmed in FIG. 4, each of the groups administered with thelong-acting derivative of SEQ ID NO: 20 (8.8 nmol/kg, injection onceevery 2 days) alone showed a decrease in body weight by −25% and −29%,respectively, compared to that before administration. Additionally, theeffect of reducing body weight was shown to increase further whenadministered in combination with the long-acting exendin derivative. Itwas also confirmed that the combined administration of the long-actingexendin derivative and the long-acting derivative of SEQ ID NO: 20 at aratio of 1:1, 1:3, and 1:10 further increased the effect of reducingbody weight by −50% or higher. Additionally, the effect of reducing bodyweight according to the ratio between the long-acting exendin derivativeand the long-acting derivative of SEQ ID NO: 20 was not significant,however, the effect of anorexia became higher along with the increase inthe percentage of the long-acting exendin derivative, thus confirmingthat the glucagon long-acting derivative of the present invention couldplay an additional role in body weight reduction in addition to theeffect of anorexia.

Additionally, as a result of the measurement of the total cholesterol inthe blood, as can be confirmed in FIG. 5, each of the groupsadministered with the long-acting exendin derivative (4.4 nmol/kg,injection once every 2 days) and the long-acting derivative of SEQ IDNO: 20 (8.8 nmol/kg, injection once every 2 days) showed a decrease incholesterol by −35% and −71%, respectively. From the above, it wasconfirmed that the glucagon long-acting derivative of the presentinvention could play an additional role in reducing blood cholesterol inaddition to the effect of anorexia. Statistical analysis was performedto compare between the excipient group (control group) and test groupsby 1-way ANOVA.

Those of ordinary skill in the art will recognize that the presentinvention may be embodied in other specific forms without departing fromits spirit or essential characteristics. The described embodiments areto be considered in all respects only as illustrative and notrestrictive. The scope of the present invention is therefore indicatedby the appended claims rather than by the foregoing description. Allchanges which come within the meaning and range of equivalency of theclaims are to be embraced within the scope of the present invention.

1. A method for treating metabolic syndrome, comprising administering(i) an isolated peptide or (ii) an isolated conjugate in which theisolated peptide is linked to a biocompatible material capable ofincreasing in vivo half-life, to a subject in need thereof, wherein thepeptide comprises an amino acid sequence selected from the groupconsisting of SEQ ID NOS: 20, 22, 27, and
 37. 2. The method of claim 1,comprising administering (i) an isolated peptide comprising an aminoacid sequence selected from the group consisting of SEQ ID NOS: 20, 22,and 27 or (ii) an isolated conjugate in which the isolated peptide islinked to a biocompatible material capable of increasing in vivohalf-life, to a subject in need thereof, wherein the metabolic syndromeis selected from the group consisting of impaired glucose tolerance,hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension,nonalcoholic steatohepatitis (NASH), atherosclerosis caused bydyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease,and stroke.
 3. The method of claim 1, comprising administering (i) anisolated peptide comprising the amino acid sequence of SEQ ID NO: 37 or(ii) an isolated conjugate in which the isolated peptide is linked to abiocompatible material capable of increasing in vivo half-life, to asubject in need thereof, wherein the metabolic syndrome is selected fromthe group consisting of impaired glucose tolerance, dyslipidemia,diabetes, hypertension, atherosclerosis caused by dyslipidemia,atherosclerosis, arteriosclerosis, coronary heart disease, and stroke.4. The method of claim 1, wherein an amino acid pair of X16 and X20 isrespectively glutamic acid and lysine, which is capable of forming aring.
 5. The method of claim 1, wherein the C-terminus of the peptide isamidated.
 6. The method of claim 1, wherein the biocompatible materialis selected from the group consisting of polyethylene glycol, fattyacid, cholesterol, albumin and a fragment thereof, an albumin-bindingmaterial, a polymer of repeating units of a particular amino acidsequence, an antibody, an antibody fragment, an FcRn-binding material,in vivo connective tissue or a derivative thereof, a nucleotide,fibronectin, transferrin, and a polysaccharide.
 7. The method of claim1, wherein the peptide is linked to the biocompatible material by alinker selected from the group consisting of polyethylene glycol,polypropylene glycol, an ethylene glycol-propylene glycol copolymer,polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide, polyvinylethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA),lipid polymer, chitin, hyaluronic acid, fatty acid, a nucleotide, and acombination thereof.
 8. The method of claim 1, wherein the biocompatiblematerial is a polypeptide comprising an immunoglobulin Fc region.
 9. Themethod of claim 1, further comprising administering a compound ormaterial having a therapeutic activity for metabolic syndrome, saidadministering being either before or after the administration of theisolated peptide or conjugate.
 10. The method of claim 9, wherein thecompound or material having a therapeutic activity for metabolicsyndrome is selected from the group consisting of an insulinotropicpeptide, a glucagon-like peptide-1 (GLP-1) receptor agonist, a leptinreceptor agonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, a Y5receptor antagonist, a melanin-concentrating hormone (MCH) receptorantagonist, a Y2/4 receptor agonist, a melanocortin 3/4 (MC 3/4)receptor agonist, a gastric/pancreatic lipase inhibitor, an agonist of5-hydroxytryptamine receptor 2C (5HT2C), a β3A receptor agonist, anamylin receptor agonist, a ghrelin antagonist, a ghrelin receptorantagonist, a peroxisome proliferator-activated receptor alpha (PPARα)agonist, a peroxisome proliferator-activated receptor delta (PPARδ)agonist, a Farnesoid X receptor (FXR) agonist, an acetyl-CoA carboxylaseinhibitor, a peptide YY, cholecystokinin (CCK), xenin, glicentin,obestatin, secretin, nesfatin, insulin, and a glucose-dependentinsulinotropic peptide (GIP).
 11. The method of claim 10, wherein theinsulinotropic peptide is selected from the group consisting of GLP-1,exendin-3, exendin-4, an agonist thereof, a derivative thereof, afragment thereof, a variant thereof, and a combination thereof.
 12. Themethod of claim 11, wherein the insulinotropic peptide is aninsulinotropic peptide derivative, in which the N-terminal histidineresidue is substituted with one selected from the group consisting ofdesamino-histidyl, N-dimethyl-histidyl, β-hydroxy imidazopropionyl,4-imidazoacetyl, and β-carboxy imidazopropionyl.
 13. The method of claim11, wherein the insulinotropic peptide is selected from the groupconsisting of a native exendin-4; an exendin-4 derivative in which theN-terminal amine group of exendin-4 is deleted; an exendin-4 derivativein which the N-terminal amine group of exendin-4 is substituted with ahydroxyl group; an exendin-4 derivative in which the N-terminal aminegroup of exendin-4 is modified with a dimethyl group; an exendin-4derivative in which the α-carbon of the 1^(st) amino acid of exendin-4,histidine, is deleted; an exendin-4 derivative in which the 12^(th)amino acid of exendin-4, lysine, is substituted with serine, and anexendin-4 derivative in which the 12^(th) amino acid of exendin-4,lysine, is substituted with arginine.
 14. A method for treatinghypoglycemia, comprising administering (i) an isolated peptide or (ii)an isolated conjugate in which the isolated peptide is linked to abiocompatible material capable of increasing in vivo half-life, to asubject in need thereof, wherein the peptide comprises an amino acidsequence selected from the group consisting of SEQ ID NOS: 20, 22, and27.
 15. The method of claim 14, wherein, an amino acid pair of X16 andX20 is respectively glutamic acid and lysine, which is capable offorming a ring.
 16. The method of claim 14, wherein the C-terminus ofthe peptide is amidated.
 17. The method of claim 14, wherein thebiocompatible material is selected from the group consisting ofpolyethylene glycol, fatty acid, cholesterol, albumin and a fragmentthereof, an albumin-binding material, a polymer of repeating units of aparticular amino acid sequence, an antibody, an antibody fragment, anFcRn-binding material, in vivo connective tissue or a derivativethereof, a nucleotide, fibronectin, transferrin, and a polysaccharide.18. The method of claim 14, wherein the peptide is linked to thebiocompatible material by a linker selected from the group consisting ofpolyethylene glycol, polypropylene glycol, an ethylene glycol-propyleneglycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, apolysaccharide, polyvinyl ethyl ether, polylactic acid (PLA),polylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,fatty acid, a nucleotide, and a combination thereof.
 19. The method ofclaim 14, wherein the biocompatible material is a polypeptide comprisingan immunoglobulin Fc region.
 20. The method of claim 14, furthercomprising administering a compound or material having a therapeuticactivity for hypoglycemia, said administering being either before orafter the administration of the isolated peptide or conjugate.